

1 **Plasma Microbial Cell-free DNA Sequencing from Over 15,000 Patients Identified a Broad Spectrum of**  
2 **Pathogens**

3 Sarah Y. Park<sup>a</sup>, Eliza J Chang<sup>a</sup>, Nathan Ledebor<sup>b</sup>, Kevin Messacar<sup>c</sup>, Martin S. Lindner<sup>a</sup>, Shivkumar  
4 Venkatasubrahmanyam<sup>a</sup>, Sivan Bercovici<sup>a</sup>, Judith C. Wilber<sup>a</sup>, Marla Lay Vaughn<sup>a</sup>, Bradley A. Perkins<sup>a</sup>, and  
5 Frederick S. Nolte<sup>a\*</sup>

6 <sup>a</sup>Karius, Redwood City, CA

7 <sup>b</sup>Medical College of Wisconsin, Milwaukee, WI

8 <sup>c</sup>University of Colorado, Children's Hospital Colorado, Aurora, CO.

9 \*Corresponding author contact information:

10 Karius, Inc.

11 975 Island Drive, Suite 101

12 Redwood City, CA 94065

13 [rick.nolte@kariusdx.com](mailto:rick.nolte@kariusdx.com)

14

15 **Abstract word count:** 276

16 **Text word count:** 3,702

17

18 **Keywords:** microbial cell-free DNA, high-throughput nucleic acid sequencing, liquid biopsy for infectious  
19 diseases, metagenomics

20 **ABSTRACT**

21 Microbial cell-free DNA (mcfDNA) sequencing is an emerging infectious disease diagnostic tool which  
22 enables unbiased pathogen detection from plasma. The Karius Test<sup>®</sup>, a commercial mcfDNA sequencing  
23 assay developed by and available since 2017 from Karius, Inc. (Redwood City, CA), detects and quantifies  
24 mcfDNA as molecules/ $\mu$ l in plasma. The commercial sample data and results for all tests conducted  
25 from April 2018 through mid-September 2021 were evaluated for laboratory performance metrics,  
26 reported pathogens, and data from test requisition forms. A total of 18,690 reports were generated  
27 from 15,165 patients in a hospital setting among 39 states and the District of Columbia. The median  
28 time from sample receipt to reported result was 26 hours (IQR 25–28), and 96% of samples had valid  
29 test results. Almost two-thirds (65%) of patients were adults, and 29% at the time of diagnostic testing  
30 had ICD10 codes representing a diverse array of clinical scenarios. There were 10,752 (58%) reports that  
31 yielded at least one taxon for a total of 22,792 detections spanning 701 unique microbial taxa. The 50  
32 most common taxa detected included 36 bacteria, 9 viruses, and 5 fungi. Opportunistic fungi (374  
33 *Aspergillus* spp., 258 *Pneumocystis jirovecii*, 196 *Mucorales*, and 33 dematiaceous fungi) comprised 861  
34 (4%) of all detections. Additional diagnostically challenging pathogens (247 zoonotic and vector borne  
35 pathogens, 144 *Mycobacteria*, 80 *Legionella* spp., 78 systemic dimorphic fungi, 69 *Nocardia* spp., and 57  
36 protozoan parasites) comprised 675 (3%) of all detections. We report the largest cohort of patients  
37 tested using plasma mcfDNA sequencing. The wide variety of pathogens detected by plasma mcfDNA  
38 sequencing reaffirm our understanding of the ubiquity of some infections while also identifying taxa less  
39 commonly detected by conventional methods.

40

## 41 INTRODUCTION

42 Sequencing microbial cell-free DNA (mcfDNA) in plasma represents integration of progress in  
43 genomic sequencing, computation analyses, and recognition of cell-free DNA as a clinically useful blood  
44 analyte (1-3). Over the last four decades, PCR-based tests, specifically multiplexed broad syndromic  
45 panels, have made welcomed contributions to infectious disease diagnostics but fall short of desired  
46 performance including breadth of pathogen detection and require samples of infected tissue or body  
47 fluid (4). Broad range PCR testing arguably facilitates considering a wider range of potential pathogens  
48 but is still only limited to bacteria and fungi (5). A recent meta-analysis, which included 20 studies that  
49 satisfied the Quality Assessment of Diagnostic Accuracy Studies (6) to assess the diagnostic accuracy of  
50 next generation sequencing in distinguishing infectious diseases, concluded that this group of  
51 technologies demonstrated satisfactory diagnostic performance for infections and yielded an overall  
52 detection rate superior to conventional methods (7). Four of the studies included in this review  
53 employed plasma mcfDNA sequencing. Moreover, early experience with plasma mcfDNA sequencing  
54 suggests this new approach, especially when applied early in a patient's clinical course and for specific  
55 use cases, has potential to improve upon the above-noted shortcomings (8, 9). Plasma mcfDNA  
56 sequencing enables unbiased pathogen detection through noninvasive sampling with rapid turnaround,  
57 creating opportunities to enhance diagnosis of bloodstream and deep-seated infections (10-12). This is  
58 urgently needed particularly among immunocompromised patients who are often the most vulnerable  
59 to serious and frequently life-threatening infections.

60 The Karius Test<sup>®</sup> is an analytically and clinically validated mcfDNA sequencing test, commercially  
61 available for US inpatients since 2017 as a laboratory developed test from Karius, Inc. The test can  
62 identify and quantitate molecules/ $\mu$ l (MPM) mcfDNA in plasma from >1,500 bacteria, DNA viruses, fungi,  
63 and parasites. The analytical and clinical validation of the test was previously reported (12). Since the  
64 time of this study, others have reported how this unbiased test may contribute to the diagnosis and

65 management of life-threatening infections in defined patient populations, specifically  
66 immunocompromised patients early in their clinical course, by creating the potential to minimize  
67 invasive procedures (13), reducing time to specific etiologic diagnosis of infections compared with  
68 standard of care (SOC) microbiological testing (14), and, in some cases, optimizing antimicrobial therapy  
69 (15, 16). In contrast, several retrospective, observational reviews of Karius Test utilization concluded  
70 that in routine clinical practice the diagnostic and clinical impact of the test was limited, which highlights  
71 the need for diagnostic stewardship to optimize implementation and maximize clinical utility in specific  
72 patient populations (17-19).

73 Plasma mcfDNA sequencing for infectious disease diagnosis performance at scale with respect  
74 to time to results, quality metrics, positivity rates, and diversity of taxa detected has not been previously  
75 reported. Here we review the results for a large commercial laboratory testing cohort of over 18,000  
76 plasma samples from over 15,000 patients in a hospital setting with the primary objective to provide  
77 additional insights about the breadth and depth of microbial identifications. In the course of doing so,  
78 we also describe the current test performance metrics and characterize clinical use based on the limited  
79 available data.

## 80 MATERIAL AND METHODS

81 **Commercial laboratory test cohort.** The Karius Test results for patients from across the United  
82 States were evaluated for reported pathogens and patient data (including basic demographics, ordering  
83 clinician, and ICD-10 codes if provided) obtained from the test request forms (TRF) for all samples tested  
84 from April 1, 2018 through mid-September, 2021. Laboratory performance metrics were gathered for  
85 all samples collected from April 1, 2018 through the end of September, 2021. Diagnosis codes  
86 submitted via TRFs were summarized at both the chapter level and Clinical Classifications Software

87 Refined Categories (20, 21). Immunocompromising conditions were then flagged using definitions  
88 published by the Agency for Healthcare Research and Quality (22-24).

89 **The Karius Test.** Plasma mcfDNA sequencing was performed as previously described (12) in the  
90 Karius clinical laboratory, certified under the Clinical Laboratory Improvement Amendments of 1988 and  
91 accredited by the College of American Pathologists. Briefly, whole-blood samples were collected in  
92 either BD Vacutainer plasma preparation tubes (PPTs) or K2-EDTA tubes. After plasma has been  
93 separated from cells, the sample is stable at ambient temperature for 96 hours and at -20°C for 6  
94 months. Upon receipt at Karius, controls for carry-over, sequencing bias, metagenomic sequencing  
95 quality, and sample mix-ups were added to the sample. Proprietary chemistries were used to enrich  
96 samples for mcfDNA without preselecting pathogens to test. Automated DNA extraction and  
97 sequencing library preparation protocols were optimized for high speed and low pathogen bias. Single-  
98 end, 76-cycle sequencing was performed on NextSeq 500 instruments (Illumina, San Diego, CA) with an  
99 average of >20 million reads/sample. Double-unique dual indexes were used to ensure robust sample  
100 demultiplexing. Sequencing data were processed using a proprietary analytical pipeline, and microbial  
101 reads were aligned to a database comprising >20,000 curated assemblies from >16,000 species of which  
102 >1,500 taxa are reported, including bacteria, DNA viruses, fungi, and parasites  
103 (<https://kariusdx.com/the-karius-test/pathogen-list/>).

104 Microorganisms present in statistically significant amounts were reported as a concentration of  
105 their mcfDNA expressed as MPM, a unique, absolute quantification capability of the Karius Test shown  
106 in preliminary work to correlate well with single-analyte quantitative PCR measurements (25, 26). The  
107 reports also contained median and range of MPM values observed for each microorganism reported in  
108 the last 1,000 specimens, as MPM values from different microbes are not comparable, and a reference  
109 interval determined from 675 asymptomatic donors for comparison. We routinely analyzed the raw  
110 data for mcfDNA from potential pathogens, including those present at levels below our standard

111 laboratory report thresholds. For this study, we focused on microorganisms identified in statistically  
112 significant amounts.

113 Notable improvements in the test wet bench procedures and analytical pipeline, as may be  
114 anticipated, occurred during the study period. We used the operational classes of pathogens described  
115 by Relman, Falkow, and Ramakrishnan (27). The operational classes include obligate, commensal,  
116 zoonotic, and environmental pathogens.

117 **Data analytics.** Data analysis and visualization were conducted using Python v. 3.9.7, pandas v.  
118 1.3.4, matplotlib v. 3.4.3, and seaborn v. 0.11.2 (28-30). Given the taxonomy and nomenclature for  
119 some genera continue to evolve, we selected three (*Legionella*, *Nocardia*, and *Mycobacterium*) to  
120 examine species detections, especially multiple species co-detections, more closely.

## 121 **RESULTS**

122 **Test cohort.** A total of 19,739 samples meeting collection and transport requirements were  
123 tested from 16,172 patients in a hospital setting in 39 states and the District of Columbia during the  
124 study period. The median time from sample receipt at the Karius laboratory to reported result was 26  
125 hours (IQR 25–28), and 96% of samples had valid test results. A summary of key performance metrics  
126 for the test in this production data set are shown in **Table 1**. These metrics were not significantly  
127 different (two-sided t-test p-value >0.01) from those reported for the first 2,000 clinical samples run by  
128 the Karius clinical laboratory and reported in the initial validation study (12). Infectious disease and  
129 hematology/oncology providers represented most ordering clinicians, 64% (n=9,804) and 14% (n=2,132),  
130 respectively, for the 15,424 specimens with a National Provider Identifier indicated. We were able to  
131 capture and analyze 18,690 reports from 15,165 patients. Twelve percent (n=1,839) of patients had at  
132 least one repeat test during the study interval. Almost two thirds (65%, n=9,798) of patients were adults  
133 (i.e., age >18 years). More than a quarter (29%, n=4,423) of patients at the time of diagnostic testing

134 had ICD10 codes representing a diverse array of clinical scenarios indicated in their TRFs (**Table 2**).  
135 Eighteen percent (n=797) of these patients were indicated as immunocompromised (IC); 717 (16%) had  
136 fever; and 230 (5%) had sepsis.

137 **Taxa detection and quantification.** Of samples yielding a valid result, 7,938 (42%) reported a  
138 negative test with no pathogens identified. The remaining 10,752 (58%) Karius Test reports from 8,849  
139 patients had at least one microbe identified (5,531 [30%] only one) representing 701 unique microbial  
140 taxa (526 [75%] bacteria, 103 [15%] fungi, 47 [7%] viruses, and 24 [3%] parasites) and a total of 22,792  
141 detections. The overall frequency of detection for each of these groups is shown in **Fig. 1**, and the  
142 number of detected taxa counts per report for all positive reports is shown in **Fig. 2**. All the quality  
143 control metrics were met for taxa quantification in MPM for 9,690 (90%) samples with positive results.  
144 A complete list of all taxa reported along with their frequency of detection and median and IQR for the  
145 MPM values are given in **Supplemental Table 1**.

146 **Top 50 reported taxa.** The top 50 reported taxa and the median, range, and IQR of MPM for  
147 each taxon are shown in **Table 3**. They included 36 bacteria, 9 viruses, and 5 fungi. Together the top 50  
148 taxa included a broad range of commensal and environmental pathogens and represented 15,692  
149 detections (69% of all detections).

150 The distribution of these taxa are as follows. There were 11,023 detections of bacteria including  
151 11 anaerobes (2,730, 25%), 8 *Streptococcus* spp. (1,379, 12%), 4 *Enterobacterales* (2,031, 18%), 3  
152 *Staphylococcus* spp. (1,369, 12%), 2 *Rothia* spp. (564, 5%), 2 *Haemophilus* spp. (466, 4%), 2 *Enterococcus*  
153 spp. (1,092, 10%), and 1 each of *Acinetobacter haemolyticus* (199, 2%), *Pseudomonas aeruginosa* (817,  
154 7%), *Stenotrophomonas maltophilia* (169, 1%), and *Helicobacter pylori* (207, 2%). There were 3,982 viral  
155 detections of 9 different viruses that included 1,275 (32%) cytomegalovirus, 902 (23%) Epstein-Barr  
156 virus, 479 (12%) herpes simplex virus 1, 468 (12%) human herpes virus 6B, 354 (9%) BK polyoma virus,  
157 171 (4%) human adenovirus C, 135 (3%) torque teno virus (TTV), 100 (3%) human adenovirus B, and 98

158 (3%) human herpes virus 7. Finally, there were 920 detections of fungi comprising 260 (28%) *Candida*  
159 *albicans*, 258 (28%) *Pneumocystis jirovecii*, 186 (20%) *Aspergillus fumigatus*, 113 (12%) *Candida*  
160 *glabrata*, and 103 (11%) *Candida tropicalis*.

161 **Difficult to diagnose uncommon pathogens.** The SOC methods for the organisms listed below  
162 have considerable shortcomings including, but not limited to, sensitivity and specificity,  
163 comprehensiveness, accuracy, time to result, and/or local availability.

164 Bacteria. The frequency distribution of the number of detections of *Legionella*-like organisms  
165 (n=80) is shown in **Fig. 3**. Forty-one percent of these detections were the most recognized pathogen, *L.*  
166 *pneumophila*. Two reports contained co-detections of two different species (*L. brunensis*, 400 MPM and  
167 *L. hackeliae*, 270 MPM; and *L. feeleii*, 78,508 MPM and *L. tunisiensis*, 76,445 MPM, respectively).  
168 Neither *L. brunensis* nor *L. tunisiensis* has been associated with human disease  
169 (<https://specialpathogenslab.com/legionella-species/>), and the MPM values for the co-detections in  
170 each report were similar.

171 The frequency distribution of *Nocardia* spp. detections, n=76, is shown in **Fig. 4**. Plasma  
172 mcfDNA sequencing detected 25 of the approximately 100 validly named species. Of the 8 species  
173 reported to be isolated more frequently from patients, 7 were detected (**Fig. 4**). One species, *N.*  
174 *cyriacigeorgica*, dominated with 19 (25%) detections. Of the 69 patient reports represented by the  
175 *Nocardia* spp. detections, 12 (17%) reported  $\geq 2$  concurrent species (range 2–5). All the co-detections  
176 were reported with similar MPM values, and 8 (67%) were co-detections of closely related species (4 *N.*  
177 *exalbida/gamkensis*, 3 *N. elegans/nova/africana*, 1 *N. kruczakiae/violaceofusca/aobensis*) previously  
178 reported to be indistinguishable by mcfDNA sequencing (31, 32).

179 The frequency distribution of the 156 *Mycobacterium* spp. detections is shown in **Fig 5**. Plasma  
180 mcfDNA sequencing detected 107 (69%) slowly growing mycobacteria (SGM) and 49 (31%) rapidly



181 growing mycobacteria (RGM). The frequency of species distributions of these three genera showed  
182 similarities in that several species were predominant, followed by long tails of uncommon to single  
183 species detections. We reported  $\geq 2$  concurrent species (range 2–6) in 6 (4%) of the 144 reports  
184 including *Mycobacterium* spp. All the co-detections were reported with similar MPM values. Three of  
185 the reports contained *M. avium complex/chimera* and one each *M. avium complex/celatum/kyorinense*,  
186 *M. brisbanense/mucogenicum/obuense*, and *M. chubuense/elephantis/flavescens/goodii/holsaticum*  
187 */phlei*. The co-detections of multiple *Legionella*, *Nocardia*, and *Mycobacterium* spp., respectively, within  
188 the same patient are shown in **Supplemental Table 2**.

189 The frequency distribution of the 247 (3% of all bacterial detections) zoonotic and vector borne  
190 bacterial detections are shown in **Fig. 6**. *Bartonella henselae* predominated with 90 (36%) detections.

191 Fungi. The frequency distribution of the 632 *Candida* spp. detections is shown in **Fig 7**; 374  
192 *Aspergillus* spp. detections in **Fig 8**; 196 detections in the order *Mucorales* in **Fig. 9**; 78 detections of the  
193 systemic dimorphic fungi in **Fig. 10**; and 33 detections of dematiaceous fungi in **Fig. 11**. We detected 9  
194 microsporidia, including 5 *Enterocytozoon bieneusi* and one each of *E. cuniculi*, *E. hellem*, *Anncaliia*  
195 *algerae*, and *Vittaforma corneae*. In addition, *Pneumocystis jirovecii* (258 detections) was among the  
196 top 50 taxa detected.

197 Eukaryotic parasites. The frequency distribution of the 57 (89% of 64 parasite detections)  
198 protozoa is shown in **Fig. 12**. Among the protozoan parasite detections, 68% were *Toxoplasma gondii*,  
199 and 14% were pathogenic amoebae. Among the 7 (11%) helminthic parasites, we detected 4  
200 nematodes (all *Strongyloides stercoralis*), 2 cestodes (both *Echinococcus multilocularis*), and 1  
201 trematode (*Schistosoma mansoni*).

202 **DISCUSSION**

203           We report the largest testing cohort of patients in which mcfDNA was identified and quantified.  
204   The key test performance metrics in this large cohort mirror what was reported with a much smaller  
205   cohort in the initial validation study (10), demonstrating that the Karius Test is robust and can be  
206   performed at scale in a clinically relevant time frame. These mcfDNA sequencing data reaffirm the  
207   ubiquity of some infections, as commonly expected microbes were detected in most patients while less  
208   common microbes were rarely detected. However, notably, the unbiased approach of the plasma  
209   mcfDNA sequencing made those “rare” detections possible, whereas conventional diagnostics require  
210   targeting specific organisms. Identifying optimal utilization, both clinical indications and timing, of the  
211   plasma mcfDNA sequencing in future studies to augment clinical decision-making and integration into  
212   current testing algorithms (17, 18, 33-35) will serve to improve the utility of the test. Examples of such  
213   studies include two recently completed prospective, observational clinical trials of the use of the Karius  
214   Test to diagnose pneumonia in immunocompromised patients (NCT04047719) (36) and infections in  
215   stem cell transplant inpatients and outpatients over time (NCT02804464) (26), respectively.

216           Our finding that 58% of the Karius Test reports identified  $\geq 1$  pathogen is substantially lower than  
217   the 70–85% reported for the test when applied to well-defined clinical uses (13, 14, 37). These findings  
218   support the need for diagnostic stewardship and additional clinical studies demonstrating how yield  
219   differs and should be carefully interpreted according to the specific patient population and disease  
220   prevalence considered.

221           The Karius Test quantitates detections in MPM, which can be influenced by several factors  
222   specific to the microbial genome—e.g., turnover rate and genome size (12). Confounding patient  
223   variables (e.g., infection site, therapeutic interventions, and immune status) may also influence this  
224   measure. Generally higher concentrations have been found in definite infections, but since considerable  
225   overlap of MPM values exists in unlikely infections and in the asymptomatic cohort, threshold values for  
226   definite infections have not been established (12). However, following the decay of mcfDNA

227 quantitatively by serial testing may have important implications for individual patient management in  
228 assessing the effectiveness of antimicrobial therapy and other medical or surgical interventions (8, 38,  
229 39), but needs further study.

230 Notable among the most common detections were the many commensal bacterial and fungal  
231 pathogens that cause serious and often invasive infections in patients with relevant risk factors (e.g.,  
232 immunocompromised). Among the viruses most detected by the Karius Test (e.g., *Herpesviridae*), all  
233 could represent latent infection, reactivation, or active infections depending on the respective clinical  
234 conditions; regardless, the detection of these viruses may be of particular concern for  
235 immunocompromised patients for whom they may cause considerable morbidity (40).

236 A key benefit of unbiased mcfDNA sequencing identified in this study is the ability to detect  
237 diagnostically challenging microbes such as opportunistic and systemic dimorphic fungi and zoonotic  
238 and vector borne pathogens (41). These pathogens often carry a sense of urgency for the management  
239 of the individual patient and even for the public's health, as they may be associated with considerable  
240 morbidity and potential mortality. As some are uncommonly expected pathogens, they present a major  
241 challenge for clinicians in considering and ordering appropriate SOC testing to capture all possible  
242 pathogens. For the laboratories, the microbiologic diagnosis of these infections often represents a  
243 major challenge for SOC methods as has been described by others (42, 43).

244 The absence of certain pathogens such as the emerging, multidrug resistant *C. auris* among the  
245 detections may arguably reflect the relatively few cases occurring during the study period in the  
246 geographic locations or patient populations of the test cohort and reflects the rarity of clinical cases in  
247 the United States (44). Plasma mcfDNA sequencing has the potential to contribute to the greater  
248 understanding of the geographic distribution of microbes and even overall disease surveillance, as  
249 demonstrated by the systemic dimorphic fungi detections. At 43 detections (55% of dimorphic fungal

250 identifications), *Histoplasma capsulatum* predominated, very likely related to its wide geographic range  
251 and opportunities for environmental exposure and mirrors what is known about the epidemiology and  
252 incidence of systemic dimorphic fungal infections (45). The relative frequency of detections of  
253 *Coccidioides immitis* and *posadasii* and *Blastomyces dermatidis* may have been influenced by the  
254 geographic bias in this study sample cohort. Of the nine *Cryptococcus* spp. detected, *gattii* was detected  
255 only once compared with *neoformans*, reflecting its restricted geographic distribution and the overall  
256 rarity of infections in the United States (46).

257         Among the rarely detected microbes during the study period are some deserving further  
258 mention. The detection of *Legionella*, an obligate pathogen, signals public health concern, whether  
259 community or hospital acquired. *L. pneumophila* serogroup 1 (LP1) is estimated to cause 84% of  
260 community acquired Legionnaire's disease (LD) (47); however, other serogroups of *L. pneumophila* and  
261 other *Legionella* spp. may cause 60% of hospital acquired LD (48). Urinary antigen detection is the most  
262 common diagnostic in the United States and Europe; yet, given its specificity for LP1, as many as 40–50%  
263 of patients with non-LP1 legionellosis could be missed (49, 50). Plasma mcfDNA sequencing provides  
264 comprehensive testing for *Legionella* and *Legionella*-like organisms in one diagnostic test and could  
265 thereby expand the known LD epidemiology, particularly in nosocomial cases.

266         *Nocardia* have 8 species-specific drug susceptibility patterns (51). While accurate species  
267 identification can predict antimicrobial susceptibility patterns, molecular methods are required for  
268 accurate identifications but are not widely available. The Karius Test detected in our cohort 7 of the 8  
269 species with recognized susceptibility patterns and can provide results more rapidly than existing  
270 approaches to species identification.

271         Finally, culture for mycobacteria, while a complicated and lengthy process, is considered the  
272 gold standard, supplemented by direct detection of *M. tuberculosis* complex by nucleic acid

273 amplification tests (NAATs) in many laboratories. However, NAATs for the direct detection of  
274 nontuberculous mycobacteria are not widely available, and accurate identification to species level from  
275 cultured isolates remains challenging for most laboratories. The *M. chimaera* may be overrepresented  
276 in our cohort since the Karius Test was optimized for its detection following reports of infections  
277 occurring post-surgeries employing contaminated cardiopulmonary bypass devices (52). However,  
278 these detections demonstrate the capability of mcfDNA sequencing to provide comprehensive  
279 identification of these important obligate and commensal pathogens directly from plasma and provides  
280 increased diagnostic value to the above-mentioned SOC methods (53).

281 Plasma mcfDNA sequencing offers a non-invasive means of detecting microbial infection and  
282 capturing species diversity, potentially revealing new insights on genetic complexity not resolved by  
283 current taxonomic classification. Still, our findings highlight the need to expand currently available  
284 genomic sequencing libraries as many species across various genera remain undiscovered or  
285 undescribed (54, 55). The species co-detections demonstrated among the genera we highlighted,  
286 *Legionella*, *Nocardia*, and *Mycobacteria*, specifically those occurring at similar MPM values, suggest  
287 detection of a single divergent strain, a species not in the Karius Test database, or, alternatively, true  
288 polymicrobial detections. Similar challenges exist for broad range PCR testing (5, 56) and occurred with  
289 adoption of proteomic identification by MALDI-TOF mass spectrometry (57).

290 This study has several limitations preventing us from directly comparing and fully elucidating  
291 plasma mcfDNA sequencing impact on patient care. Orthogonal testing data (including type, timing, and  
292 results) were not available for comparison with the Karius Test results; nor was information regarding  
293 antimicrobial or other therapies or procedures. Also, the clinical context for using the Karius Test was  
294 provided in only 29% of patients; that information was voluntarily provided, may have been incomplete,  
295 and would reflect the clinician's perspective at the time they ordered the test vs. the final diagnosis.  
296 However, others have reported potential increased diagnostic yield of plasma mcfDNA sequencing

297 compared with SOC tests in certain clinical scenarios (14-16, 58). Some have noted the test to be  
298 commonly applied in managing severely ill, especially IC, patients (59), who are more likely to be  
299 infected with unusual, and difficult to diagnose pathogens (60, 61).

300           Constraints of the underlying data structure prevented analyzing the data from those patients  
301 who had repeated testing to determine whether these tests were performed serially to diagnose new  
302 suspected infections or to monitor therapy response or conduct pathogen surveillance among  
303 immunocompromised patients as suggested by others (8, 26, 62-64). Further, the underlying data  
304 structure limited our ability to stratify the results by notable improvements to the bioinformatics  
305 pipeline over the course of the study period. Nevertheless, the unique data from this large testing  
306 cohort provides a wealth of information to help improve our understanding of infecting pathogens.

307           Unbiased plasma mcfDNA sequencing can potentially enhance patient outcomes by direct and  
308 timely recognition of pathogens in specific clinical scenarios as well as benefit the overall public health  
309 by increasing our understanding of the epidemiology of emerging infectious diseases such as  
310 monkeypox virus or *Borrelia miyamotoi* (M.S. Lindner, K. Brick, N. Noll, S.Y. Park, *et. al.*, submitted for  
311 publication; L.A. Rubio, A.M. Kjemtrup, G.E. Marx, S. Cronan, *et. al.*, submitted for publication,  
312 respectively). Further, this powerful, novel diagnostic tool may facilitate medical advances through  
313 recognizing previously unanticipated pathogens, as noted when mcfDNA sequencing was leveraged in a  
314 research use only modality to identify porcine cytomegalovirus infection in a patient who had received a  
315 genetically modified porcine-to-human cardiac transplant (65). As with any advanced diagnostic tool,  
316 careful, timely clinical application with expert guidance and interpretation of its results as well as  
317 appropriate diagnostic stewardship will optimize its application to offer even greater clinical impact. In  
318 addition, the development of robust clinical outcomes studies to evaluate the clinical impact and cost  
319 effectiveness of plasma mcfDNA sequencing for specific clinical indications to guide use remains a top  
320 diagnostic stewardship priority.

321 **ACKNOWLEDGEMENTS**

322 We thank the talented, experienced, and dedicated clinical laboratory operations and analytics teams at  
323 Karius for generating the test results and sequencing analyses, respectively, that were foundational to  
324 this study. We also thank T. Matthew Hill, PharmD, PhD, formerly with Karius, Inc., and Asim A. Ahmed,  
325 MD for their early contributions to the paper. This study was supported by Karius. Nathan Ledeboer,  
326 PhD and Kevin Messacar, MD, PhD both serve as uncompensated consultants for Karius on this  
327 manuscript. Their relationship with Karius has been reviewed and approved by the Medical College of  
328 Wisconsin and the University of Colorado, Children’s Hospital of Colorado, respectively, in accordance  
329 with their conflict of interest policies.

330 **REFERENCES**

- 331 1. Levy SE, Myers RM. 2016. Advancements in Next-Generation Sequencing. *Annu Rev Genomics*  
332 *Hum Genet* 17:95-115.
- 333 2. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. 1990. Basic local alignment search tool. *J*  
334 *Mol Biol* 215:403-10.
- 335 3. Kowarsky M, Camunas-Soler J, Kertesz M, De Vlaminc I, Koh W, Pan W, Martin L, Neff NF,  
336 Okamoto J, Wong RJ, Kharbanda S, El-Sayed Y, Blumenfeld Y, Stevenson DK, Shaw GM, Wolfe  
337 ND, Quake SR. 2017. Numerous uncharacterized and highly divergent microbes which colonize  
338 humans are revealed by circulating cell-free DNA. *Proc Natl Acad Sci U S A* 114:9623-9628.
- 339 4. Lewinski M, Alby K, Babady E, Butler-Wu S, Dien Bard J, Greninger A, Hanson K, Naccache S,  
340 Newton D, Temple-Smolkin RL, Nolte F. *in press*. Exploring the Utility of Multiplex Infectious  
341 Disease Panel Testing for Diagnosis of Infection in Different Body Sites: A Joint Report of the  
342 Association for Molecular Pathology, American Society for Microbiology, Infectious Diseases  
343 Society of America, and Pan American Society for Clinical Virology. *The Journal of Molecular*  
344 *Diagnostics*.
- 345 5. Naureckas Li C, Nakamura MM. 2022. Utility of Broad-Range PCR Sequencing for Infectious  
346 Diseases Clinical Decision Making: a Pediatric Center Experience. *J Clin Microbiol* 60:e0243721.
- 347 6. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, Leeflang MM, Sterne JA,  
348 Bossuyt PM, Group Q-. 2011. QUADAS-2: a revised tool for the quality assessment of diagnostic  
349 accuracy studies. *Ann Intern Med* 155:529-36.
- 350 7. Liu J, Zhang Q, Dong YQ, Yin J, Qiu YQ. 2022. Diagnostic accuracy of metagenomic next-  
351 generation sequencing in diagnosing infectious diseases: a meta-analysis. *Sci Rep* 12:21032.
- 352 8. Eichenberger EM, Degner N, Scott ER, Ruffin F, Franzone J, Sharma-Kuinkel B, Shah P, Hong D,  
353 Dalai SC, Blair L, Hollemon D, Chang E, Ho C, Wanda L, de Vries C, Fowler VG, Ahmed AA. 2022.



- 354 Microbial Cell-Free DNA Identifies the Causative Pathogen in Infective Endocarditis and Remains  
355 Detectable Longer Than Conventional Blood Culture in Patients with Prior Antibiotic Therapy.  
356 Clin Infect Dis doi:10.1093/cid/ciac426.
- 357 9. Dworsky ZD, Lee B, Ramchandar N, Rungvivatjarus T, Coufal NG, Bradley JS. 2022. Impact of Cell-  
358 Free Next-Generation Sequencing on Management of Pediatric Complicated Pneumonia. Hosp  
359 Pediatr 12:377-384.
- 360 10. Brenner T, Skarabis A, Stevens P, Axnick J, Haug P, Grumaz S, Bruckner T, Luntz S, Witzke O, Pletz  
361 MW, Ruprecht TM, Marschall U, Altin S, Greiner W, Berger MM, Group TICCT. 2021.  
362 Optimization of sepsis therapy based on patient-specific digital precision diagnostics using next  
363 generation sequencing (DigiSep-Trial)-study protocol for a randomized, controlled,  
364 interventional, open-label, multicenter trial. Trials 22:714.
- 365 11. Han D, Li R, Shi J, Tan P, Zhang R, Li J. 2020. Liquid biopsy for infectious diseases: a focus on  
366 microbial cell-free DNA sequencing. Theranostics 10:5501-5513.
- 367 12. Blauwkamp TA, Thair S, Rosen MJ, Blair L, Lindner MS, Vilfan ID, Kawli T, Christians FC,  
368 Venkatasubrahmanyam S, Wall GD, Cheung A, Rogers ZN, Meshulam-Simon G, Huijse L,  
369 Balakrishnan S, Quinn JV, Hollemon D, Hong DK, Vaughn ML, Kertesz M, Bercovici S, Wilber JC,  
370 Yang S. 2019. Analytical and clinical validation of a microbial cell-free DNA sequencing test for  
371 infectious disease. Nat Microbiol 4:663-674.
- 372 13. Rossoff J, Chaudhury S, Soneji M, Patel SJ, Kwon S, Armstrong A, Muller WJ. 2019. Noninvasive  
373 Diagnosis of Infection Using Plasma Next-Generation Sequencing: A Single-Center Experience.  
374 Open Forum Infect Dis 6.
- 375 14. Benamu E, Gajurel K, Anderson JN, Lieb T, Gomez CA, Seng H, Aquino R, Hollemon D, Hong DK,  
376 Blauwkamp TA, Kertesz M, Blair L, Bollyky PL, Medeiros BC, Coutre S, Zompi S, Montoya JG,

- 377 Deresinski S. 2021. Plasma Microbial Cell-free DNA Next Generation Sequencing in the Diagnosis  
378 and Management of Febrile Neutropenia. Clin Infect Dis doi:10.1093/cid/ciab324.
- 379 15. Yu J, Diaz JD, Goldstein SC, Patel RD, Varela JC, Reyenga C, Smith M, Smith T, Balls J, Ahmad S,  
380 Mori S. 2021. Impact of Next-Generation Sequencing Cell-free Pathogen DNA Test on  
381 Antimicrobial Management in Adults with Hematological Malignancies and Transplant  
382 Recipients with Suspected Infections. Transplant Cell Ther doi:10.1016/j.jtct.2021.02.025.
- 383 16. Francisco DMA, Woc-colburn L, Carlson TJ, Lasco T, Barrett MB, Mohajer MA. 2020. 680. The use  
384 of plasma next-generation sequencing test in the management of immunocompetent and  
385 immunocompromised patients – a single center retrospective study. Open Forum Infectious  
386 Diseases 7:S393-S394.
- 387 17. Hogan CA, Yang S, Garner OB, Green DA, Gomez CA, Dien Bard J, Pinsky BA, Banaei N. 2021.  
388 Clinical Impact of Metagenomic Next-Generation Sequencing of Plasma Cell-Free DNA for the  
389 Diagnosis of Infectious Diseases: A Multicenter Retrospective Cohort Study. Clin Infect Dis  
390 72:239-245.
- 391 18. Lee RA, Al Dhaheri F, Pollock NR, Sharma TS. 2020. Assessment of the Clinical Utility of Plasma  
392 Metagenomic Next-Generation Sequencing in a Pediatric Hospital Population. J Clin Microbiol  
393 58.
- 394 19. Niles DT, Wijetunge DSS, Palazzi DL, Singh IR, Revell PA. 2020. Plasma Metagenomic Next-  
395 Generation Sequencing Assay for Identifying Pathogens: a Retrospective Review of Test  
396 Utilization in a Large Children's Hospital. J Clin Microbiol 58.
- 397 20. National Center for Health Statistics (CDC). 2015. International Classification of Diseases, Tenth  
398 Revision, Clinical Modification (ICD-10-CM).  
399 [https://ftp.cdc.gov/pub/Health\\_Statistics/NCHS/Publications/ICD10CM/2022/icd10cm-tabular-](https://ftp.cdc.gov/pub/Health_Statistics/NCHS/Publications/ICD10CM/2022/icd10cm-tabular-2022-April-1.pdf)  
400 [2022-April-1.pdf](https://ftp.cdc.gov/pub/Health_Statistics/NCHS/Publications/ICD10CM/2022/icd10cm-tabular-2022-April-1.pdf).

- 401 21. Agency for Healthcare Research and Quality. October 2021. Clinical Classifications Software  
402 Refined (CCSR). Healthcare Cost and Utilization Project (HCUP). Rockville, MD.  
403 [https://www.hcup-us.ahrq.gov/toolssoftware/ccsr/ccs\\_refined.jsp](https://www.hcup-us.ahrq.gov/toolssoftware/ccsr/ccs_refined.jsp).
- 404 22. Agency for Healthcare Research and Quality. July 2021. Immunocompromised State Diagnosis  
405 and Procedure Codes.  
406 [https://qualityindicators.ahrq.gov/Downloads/Modules/PQI/V2021/TechSpecs/PQI\\_Appendix\\_C](https://qualityindicators.ahrq.gov/Downloads/Modules/PQI/V2021/TechSpecs/PQI_Appendix_C.pdf)  
407 [.pdf](https://qualityindicators.ahrq.gov/Downloads/Modules/PQI/V2021/TechSpecs/PQI_Appendix_C.pdf).
- 408 23. Agency for Healthcare Research and Quality. July 2021. Intermediate-Risk Immunocompromised  
409 State Diagnosis Codes.  
410 [https://qualityindicators.ahrq.gov/Downloads/Modules/PDI/V2021/TechSpecs/PDI\\_Appendix\\_G](https://qualityindicators.ahrq.gov/Downloads/Modules/PDI/V2021/TechSpecs/PDI_Appendix_G.pdf)  
411 [.pdf](https://qualityindicators.ahrq.gov/Downloads/Modules/PDI/V2021/TechSpecs/PDI_Appendix_G.pdf).
- 412 24. Agency for Healthcare Research and Quality. July 2021. High-Risk Immunocompromised State  
413 Diagnosis and Procedure Codes.  
414 [https://qualityindicators.ahrq.gov/Downloads/Modules/PDI/V2021/TechSpecs/PDI\\_Appendix\\_F](https://qualityindicators.ahrq.gov/Downloads/Modules/PDI/V2021/TechSpecs/PDI_Appendix_F.pdf)  
415 [.pdf](https://qualityindicators.ahrq.gov/Downloads/Modules/PDI/V2021/TechSpecs/PDI_Appendix_F.pdf).
- 416 25. Blauwkamp TA, Ho C, Seng H, Hollemon D, Blair L, Yao JD, Warren D, Russell P, Davis T, Hong DK.  
417 2019. Evaluation of Karius plasma next generation sequencing of microbial cell-free DNA to  
418 detect and quantitate Cytomegalovirus, Epstein-Barr Virus, and BK Virus, abstr American Society  
419 for Microbiology (ASM) Microbe 2019, San Francisco, CA,
- 420 26. Fung M, Teraoka J, Lien K, Seng H, Parham A, Hollemon D, Hong DK, Blair L, Zompì S, Logan AC,  
421 Yao JD, Chin-Hong P. 2019. Use of the quantitative Karius® plasma next generation sequencing  
422 cell-free pathogen DNA test to detect and monitor Cytomegalovirus infection in allogeneic stem-  
423 cell transplant recipients, abstr 2019 TCT: Transplantation & Cellular Therapy Meetings of  
424 ASBMT and CIBMTR, Houston, TX,

- 425 27. Relman DA, Falkow S, Ramakrishnan L. 2020. Chapter 1: A Molecular Perspective of Microbial  
426 Pathogenicity, p 1-11. *In* Bennett JE, Bennett JE, Dolin R, Blaser MJ (ed), Mandell, Douglas, and  
427 Bennett's principles and practice of infectious diseases, Ninth edition. ed, vol 1. Elsevier,  
428 Philadelphia, PA.
- 429 28. McKinney W. Data structures for statistical computing in python, abstr 9th Python in Science  
430 Conference, Austin, TX, June 28 - July 3, 2010.
- 431 29. Hunter J. 2007. Matplotlib: a 2D graphics environment. *Computing in Science & Engineering*.  
432 9(3):90-95. doi:10.1109/MCSE.2007.55.
- 433 30. Waskom M, Botvinnik O, O'Kane D, Hobson P, Lukauskas S, Gemperline DC, Augspurger T,  
434 Halchenko Y, Cole JB, Warmenhoven J, de Ruiter J, Pye C, Hoyer S, Vanderplas J, Villalba S,  
435 Kunter G, Quintero E, Bachant P, Martin M, Meyer K, Miles A, Ram Y, Yarkoni T, Williams ML,  
436 Evans C, Fitzgerald C, B, Fonnesebeck C, Lee A, Qalieh A. 2017. mwaskom/seaborn: v0.8.1  
437 (September 2017), September 3, 2017 ed doi:10.5281/zenodo.883859. Zenodo.
- 438 31. Ahmed AA, Rosen M, Hong DK, Dalai SC, Macintyre A, Blair L, Lindner M, Balakrishnan S,  
439 Bercovici S. Next-generation sequencing of pathogen cell-free DNA in plasma (Karius Test)  
440 reveals *Nocardia* species diversity in clinical infections, abstr ASM Microbe, San Francisco, CA,  
441 June 20-24, 2019.
- 442 32. Smollin M, Lindner M, Blair L, Arun A, Degner N, Equils O, de Vries CR, Dalai SC, MacIntyre A,  
443 Ahmed AA. Rapid, non-invasive detection of *Legionella* and *Nocardia* and resolution of species  
444 diversity in clinical infections in immunocompromised hosts using the Karius Test, a plasma-  
445 based microbial cell-free DNA sequencing test for pathogen identification, abstr 21st ICHS  
446 Symposium, Melbourne, Australia, February 17-19, 2021.

- 447 33. Graff K, Dominguez SR, Messacar K. 2021. Metagenomic Next-Generation Sequencing for  
448 Diagnosis of Pediatric Meningitis and Encephalitis: A Review. *J Pediatric Infect Dis Soc* 10:S78-  
449 S87.
- 450 34. Haslam DB. 2021. Future Applications of Metagenomic Next-Generation Sequencing for  
451 Infectious Diseases Diagnostics. *J Pediatric Infect Dis Soc* 10:S112-S117.
- 452 35. Huang AL, Hendren N, Carter S, Larsen C, Garg S, La Hoz R, Farr M. 2022. Biomarker-Based  
453 Assessment for Infectious Risk Before and After Heart Transplantation. *Curr Heart Fail Rep*  
454 doi:10.1007/s11897-022-00556-z.
- 455 36. Bergin SP, Chemaly R, Duttgupta R, Bigelow R, Dadwal S, Hill JA, Lee YJ, Haidar G, Luk A, Drelick  
456 A, Chin-Hong PV, Benamu E, Davis T, Wolf O, McClain M, Maziarz E, Madut D, Bedoya A, Gilstrap  
457 DL, Todd J, Barkauskas C, Spallone A, McDowell BJ, Small CB, Shariff D, Salsgiver E, Khawaja F,  
458 Papanicolaou GA, Spagnoletti J, Van Besien K, English M, Fung M, Rusell P, Ibrahim S, Pandey S,  
459 Adams S, Liang W, Visweswaran A, Ho C, Nemirovich-Danchenko E, Braaten J, Sundermann L,  
460 Mughar M, Chavez R, Romano R, Montgomery S, Kumar S, Dalai SC, Cho Y, Ahmed AA, et al.  
461 2022. PICKUP: Pneumonia in the ImmunoCompromised - use of the Karius Test® for the  
462 detection of Undiagnosed Pathogens abstr IDWeek 2022, Washington, D.C., October 20, 2022.
- 463 37. Farnaes L, Wilke J, Ryan Loker K, Bradley JS, Cannavino CR, Hong DK, Pong A, Foley J, Coufal NG.  
464 2019. Community-acquired pneumonia in children: cell-free plasma sequencing for diagnosis  
465 and management. *Diagn Microbiol Infect Dis* 94:188-191.
- 466 38. Eichenberger EM, de Vries CR, Ruffin F, Sharma-Kuinkel B, Park L, Hong D, Scott ER, Blair L,  
467 Degner N, Hollemon DH, Blauwkamp TA, Ho C, Seng H, Shah P, Wanda L, Fowler VG, Ahmed AA.  
468 2022. Microbial Cell-Free DNA Identifies Etiology of Bloodstream Infections, Persists Longer  
469 Than Conventional Blood Cultures, and Its Duration of Detection Is Associated With Metastatic

- 470 Infection in Patients With Staphylococcus aureus and Gram-Negative Bacteremia. Clin Infect Dis  
471 74:2020-2027.
- 472 39. To RK, Ramchandar N, Gupta A, Pong A, Cannavino C, Foley J, Farnaes L, Coufal NG. 2021. Use of  
473 Plasma Metagenomic Next-generation Sequencing for Pathogen Identification in Pediatric  
474 Endocarditis. Pediatr Infect Dis J 40:486-488.
- 475 40. de Melo Silva J, Pinheiro-Silva R, Dhyan A, Pontes GS. 2020. Cytomegalovirus and Epstein-Barr  
476 Infections: Prevalence and Impact on Patients with Hematological Diseases. Biomed Res Int  
477 2020:1627824.
- 478 41. Hilt EE, Ferrieri P. 2022. Next Generation and Other Sequencing Technologies in Diagnostic  
479 Microbiology and Infectious Diseases. Genes 13:1566.
- 480 42. Vaca DJ, Dobler G, Fischer SF, Keller C, Konrad M, von Loewenich FD, Orensa S, Sapre SU, van  
481 Belkum A, Kempf VAJ. 2022. Contemporary diagnostics for medically relevant fastidious  
482 microorganisms belonging to the genera Anaplasma, Bartonella, Coxiella, Orientia, and  
483 Rickettsia. FEMS Microbiol Rev doi:10.1093/femsre/fuac013.
- 484 43. Haydour Q, Hage CA, Carmona EM, Epelbaum O, Evans SE, Gabe LM, Knox KS, Kolls JK,  
485 Wengenack NL, Prokop LJ, Limper AH, Murad MH. 2019. Diagnosis of Fungal Infections. A  
486 Systematic Review and Meta-Analysis Supporting American Thoracic Society Practice Guideline.  
487 Ann Am Thorac Soc 16:1179-1188.
- 488 44. Centers for Disease Control and Prevention (CDC). Tracking *Candida auris*.  
489 <https://www.cdc.gov/fungal/candida-auris/tracking-c-auris.html>. Accessed December 15, 2022.
- 490 45. Lockhart SR, Toda M, Benedict K, Caceres DH, Litvintseva AP. 2021. Endemic and Other  
491 Dimorphic Mycoses in The Americas. J Fungi (Basel) 7.

- 492 46. Centers for Disease Control and Prevention (CDC). *C. gattii* Infection Statistics.  
493 <https://www.cdc.gov/fungal/diseases/cryptococcosis-gattii/statistics.html>. Accessed June 5,  
494 2022.
- 495 47. Yu VL, Plouffe JF, Pastoris MC, Stout JE, Schousboe M, Widmer A, Summersgill J, File T, Heath  
496 CM, Paterson DL, Chereschsky A. 2002. Distribution of Legionella species and serogroups isolated  
497 by culture in patients with sporadic community-acquired legionellosis: an international  
498 collaborative survey. *J Infect Dis* 186:127-8.
- 499 48. Helbig JH, Uldum SA, Bernander S, Luck PC, Wewalka G, Abraham B, Gaia V, Harrison TG. 2003.  
500 Clinical utility of urinary antigen detection for diagnosis of community-acquired, travel-  
501 associated, and nosocomial legionnaires' disease. *J Clin Microbiol* 41:838-40.
- 502 49. Fields BS, Benson RF, Besser RE. 2002. Legionella and Legionnaires' disease: 25 years of  
503 investigation. *Clin Microbiol Rev* 15:506-26.
- 504 50. Phin N, Parry-Ford F, Harrison T, Stagg HR, Zhang N, Kumar K, Lortholary O, Zumla A, Abubakar I.  
505 2014. Epidemiology and clinical management of Legionnaires' disease. *Lancet Infect Dis*  
506 14:1011-21.
- 507 51. CLSI. 2018. Performance Standards for Susceptibility Testing of Mycobacteria, Nocardia spp.,  
508 and Other Aerobic Actinomycetes. *In* (ed), CLSI Supplement M62. Clinical and Laboratory  
509 Standards Institute, Wayne, PA.
- 510 52. Sax H, Bloemberg G, Hasse B, Sommerstein R, Kohler P, Achermann Y, Rossle M, Falk V, Kuster  
511 SP, Bottger EC, Weber R. 2015. Prolonged Outbreak of Mycobacterium chimaera Infection After  
512 Open-Chest Heart Surgery. *Clin Infect Dis* 61:67-75.
- 513 53. Pollock NR, MacIntyre AT, Blauwkamp TA, Blair L, Ho C, Calderon R, Franke MF. 2021. Detection  
514 of Mycobacterium tuberculosis cell-free DNA to diagnose TB in pediatric and adult patients. *Int J*  
515 *Tuberc Lung Dis* 25:403-405.

- 516 54. Goldberg B, Sichtig H, Geyer C, Ledebuer N, Weinstock GM. 2015. Making the Leap from  
517 Research Laboratory to Clinic: Challenges and Opportunities for Next-Generation Sequencing in  
518 Infectious Disease Diagnostics. *mBio* 6:e01888-15.
- 519 55. Simner PJ, Miller S, Carroll KC. 2018. Understanding the Promises and Hurdles of Metagenomic  
520 Next-Generation Sequencing as a Diagnostic Tool for Infectious Diseases. *Clin Infect Dis* 66:778-  
521 788.
- 522 56. Wright WF, Simner PJ, Carroll KC, Auwaerter PG. 2022. Progress Report: Next-Generation  
523 Sequencing, Multiplex Polymerase Chain Reaction, and Broad-Range Molecular Assays as  
524 Diagnostic Tools for Fever of Unknown Origin Investigations in Adults. *Clin Infect Dis* 74:924-932.
- 525 57. Steensels D, Verhaegen J, Lagrou K. 2011. Matrix-assisted laser desorption ionization-time of  
526 flight mass spectrometry for the identification of bacteria and yeasts in a clinical microbiological  
527 laboratory: a review. *Acta Clin Belg* 66:267-73.
- 528 58. Camargo JF, Ahmed AA, Lindner MS, Morris MI, Anjan S, Anderson AD, Prado CE, Dalai SC,  
529 Martinez OV, Komanduri KV. 2019. Next-generation sequencing of microbial cell-free DNA for  
530 rapid noninvasive diagnosis of infectious diseases in immunocompromised hosts. *F1000Res*  
531 8:1194.
- 532 59. Edward P, Handel AS. 2021. Metagenomic Next-Generation Sequencing for Infectious Disease  
533 Diagnosis: A Review of the Literature With a Focus on Pediatrics. *J Pediatric Infect Dis Soc*  
534 10:S71-S77.
- 535 60. Fishman JA. 2022. Approach to the immunocompromised patient with fever and pulmonary  
536 infiltrates. *In* Blumberg EA, Bond S (ed), *UptoDate*, Waltham, MA.
- 537 61. Pierce KK. 2013. Chapter 40 - Immunocompromised Host, p 277-292. *In* Parsons PE, Wiener-  
538 Kronish JP (ed), *Critical Care Secrets (Fifth Edition)* doi:[https://doi.org/10.1016/B978-0-323-](https://doi.org/10.1016/B978-0-323-08500-7.00041-2)  
539 [08500-7.00041-2](https://doi.org/10.1016/B978-0-323-08500-7.00041-2). Mosby.



- 540 62. Goggin KP, Gonzalez-Pena V, Inaba Y, Allison KJ, Hong DK, Ahmed AA, Hollemon D, Natarajan S,  
541 Mahmud O, Kuenzinger W, Youssef S, Brenner A, Maron G, Choi J, Rubnitz JE, Sun Y, Tang L,  
542 Wolf J, Gawad C. 2020. Evaluation of Plasma Microbial Cell-Free DNA Sequencing to Predict  
543 Bloodstream Infection in Pediatric Patients With Relapsed or Refractory Cancer. *JAMA Oncol*  
544 6:552-556.
- 545 63. Solanky D, Ahmed AA, Fierer J, Golts E, Jones M, Mehta SR. 2022. Utility of plasma microbial cell-  
546 free DNA decay kinetics after aortic valve replacement for Bartonella endocarditis: case report.  
547 *Front Trop Dis* 3:842100.
- 548 64. Ahsouri N, Nieves D, Singh J, Arrieta A. 2022. Serial Microbial Cell-Free DNA Next Generation  
549 Sequencing (NGS) As A Means of Diagnosis and Monitoring of Clinical Response To Treatment Of  
550 Invasive Fungal Infections (IFI) In Immunocompromised Pediatric Patients, abstr IDWeek 2022,  
551 Washington, D.C., October 21, 2022.
- 552 65. Griffith BP, Goerlich CE, Singh AK, Rothblatt M, Lau CL, Shah A, Lorber M, Grazioli A, Saharia KK,  
553 Hong SN, Joseph SM, Ayares D, Mohiuddin MM. 2022. Genetically Modified Porcine-to-Human  
554 Cardiac Xenotransplantation. *N Engl J Med* 387:35-44.
- 555 66. Conville PS, Brown-Elliott BA, Witebsky FG. February 2019. *Nocardia, Rhodococcus, Gordonia,*  
556 *Actinomadura, Streptomyces,* and other aerobic actinomycetes. In Carroll KC, Pfaller MA, Landry  
557 ML, McAdam AJ, Patel R, Richter SS, Warnock DW (ed), *Manual of Clinical Microbiology*, 12th ed.  
558 ASM Press.
- 559 67. Caulfield AJ, Elvira, Brown-Elliott BA, Wallace J, Richard J., Wengenack NL. February 2019.  
560 *Mycobacterium*: laboratory characteristics of slowly growing mycobacteria other than  
561 *Mycobacterium tuberculosis*. In Carroll KC, Pfaller MA, Landry ML, McAdam AJ, Patel R, Richter  
562 SS, Warnock DW (ed), *Manual of Clinical Microbiology*, 12th ed. ASM Press.

- 563 68. Brown-Elliott BA, Wallace J, Richard J. February 2019. *Mycobacterium*: clinical and laboratory  
564 characteristics of rapidly growing mycobacteria. *In* Carroll KC, Pfaller MA, Landry ML, McAdam  
565 AJ, Patel R, Richter SS, Warnock DW (ed), *Manual of Clinical Microbiology*, 12th ed. ASM Press.
- 566 69. Centers for Disease Control and Prevention (CDC). 2022 National Notifiable Infectious Diseases.  
567 <https://ndc.services.cdc.gov/search-results-year/>. Accessed March 1, 2022.
- 568 70. Hoffmann K, Pawlowska J, Walther G, Wrzosek M, de Hoog GS, Benny GL, Kirk PM, Voigt K.  
569 2013. The family structure of the Mucorales: a synoptic revision based on comprehensive  
570 multigene-genealogies. *Persoonia* 30:57-76.
- 571

572 **Table 1.** Plasma mcfDNA sequencing test performance metrics in production, April 2018–end of  
573 September 2021.

Metric	Production <sup>1</sup>	Validation <sup>2</sup>
Sample acceptance rate	98%	98%
Total yield	96%	98%
First pass yield	91%	91%
Results delivered next operational day	90%	90%

574

575 <sup>1</sup>Based on 20,087 clinical samples received during this study.

576 <sup>2</sup>Based on 2,000 clinical samples tested as part of the initial Karius Test validation study (12)

577

**Table 2.** ICD10 codes by principal diagnosis type for those patients with ICD10 codes indicated on Karius TRFs (N=4,423), April 2018–September 2021.

Principal diagnosis type (ICD10-CM Chapter)	Total	IC	Fever	Sepsis
(Unmappable)	68			
Conditions not elsewhere classified	1437		722	
Respiratory system diseases	800			
Neoplasms	580	288		
Infectious/parasitic diseases	543	47		231
Blood diseases	485	320		
Circulatory system diseases	416			
Factors influencing health status and contact with health services	290	140		
Musculoskeletal system diseases	259	9		
Nervous system diseases	242			

Digestive system diseases	162	21		
Skin diseases	111			
Genitourinary system diseases	101	15		
Endocrine/metabolic diseases	91	4		
Injury, poisoning, external causes	83	25		
Congenital malformations	76			
Codes for special purposes	20			
Eye/adnexa diseases	16			
Mental/behavioral disorders	13			
Ear/mastoid diseases	7			
Pregnancy/childbirth	7			
External causes of morbidity	3			
<b>Total number of patients by diagnosis chapter</b>	<b>5810</b>	<b>869</b>	<b>722</b>	<b>231</b>

TRF = test report form. IC = immunocompromised. Fever: any ICD10 starting with "R50"; sepsis: any ICD10 starting with "A41"; IC: any ICD10 annotated as immunocompromised from AHRQ code list. Each TRF could contain up to 2 ICD10 codes, and each patient had between 1–5 unique ICD10 codes. For the study period, there were 15,165 patients with a positive or negative report (18,690 reports).

**Table 3.** Top 50 taxa detected by sorted microorganism group (bacteria, fungi, and viruses) and then alphabetically by taxon name with number detected and median and IQR of molecules/ $\mu\text{l}$  (MPM) values for each taxon, April 2018–September 2021.

<b>Taxon name</b>	<b>Number detected</b>	<b>Median (MPM)</b>	<b>IQR (MPM)</b>
<b>Bacteria</b>			
<i>Acinetobacter haemolyticus</i>	199	142.97	192.68
<i>Bacteroides fragilis</i>	217	264.74	1,046.15
<i>Bacteroides ovatus</i>	133	141.43	476.14
<i>Bacteroides thetaiotaomicron</i>	146	221.79	742.60
<i>Bacteroides vulgatus</i>	392	153.01	413.32
<i>Enterobacter cloacae complex</i>	343	821.34	6,742.30
<i>Enterococcus faecalis</i>	582	617.90	3,285.15
<i>Enterococcus faecium</i>	510	687.63	3,958.33
<i>Escherichia coli</i>	1088	684.92	3,623.17
<i>Fusobacterium nucleatum</i>	299	460.25	1,922.08
<i>Haemophilus influenzae</i>	288	157.09	425.59
<i>Haemophilus parainfluenzae</i>	178	284.92	1,121.19
<i>Helicobacter pylori</i>	207	217.44	601.83
<i>Klebsiella pneumoniae</i>	501	910.19	5,889.84
<i>Lactobacillus fermentum</i>	165	256.13	1,058.08
<i>Lactobacillus rhamnosus</i>	281	344.33	1,250.14
<i>Prevotella melaninogenica</i>	509	208.52	545.66

<i>Prevotella oris</i>	170	517.78	2,094.07
<i>Pseudomonas aeruginosa</i>	817	1,005.18	6,874.18
<i>Rothia dentocariosa</i>	110	117.02	256.72
<i>Rothia mucilaginosa</i>	454	177.53	369.36
<i>Serratia marcescens</i>	99	492.72	2,956.54
<i>Staphylococcus aureus</i>	561	838.21	5,665.43
<i>Staphylococcus epidermidis</i>	716	579.58	2,689.68
<i>Staphylococcus haemolyticus</i>	92	1,137.08	5,450.01
<i>Stenotrophomonas maltophilia</i>	169	1,983.18	11,864.14
<i>Streptococcus intermedius</i>	100	354.95	1,048.47
<i>Streptococcus mitis</i>	356	226.15	897.48
<i>Streptococcus oralis</i>	140	235.54	730.42
<i>Streptococcus parasanguinis</i>	186	152.35	298.03
<i>Streptococcus pneumoniae</i>	214	975.48	11,933.10
<i>Streptococcus pyogenes</i>	95	1,064.08	9,773.54
<i>Streptococcus salivarius</i>	104	253.73	799.10
<i>Streptococcus thermophilus</i>	184	190.84	339.33
<i>Veillonella dispar</i>	162	140.88	269.85
<i>Veillonella parvula</i>	256	202.30	476.57
<b>Fungi</b>			
<i>Aspergillus fumigatus</i>	186	300.10	723.60
<i>Candida albicans</i>	260	624.63	2,074.97
<i>Candida glabrata</i>	113	611.85	1,449.20



<i>Candida tropicalis</i>	103	784.49	3,997.85
<i>Pneumocystis jiroveci</i>	258	2,452.78	18,084.89
<b>Viruses</b>			
<i>BK polyomavirus</i>	354	472.38	2,677.18
Cytomegalovirus	1275	633.93	3,889.67
Epstein-Barr virus	902	272.34	852.32
Herpes simplex virus type 1	479	754.78	3,208.06
Human herpesvirus 6B	468	518.74	3,268.72
Human herpesvirus 7	98	82.74	342.37
Human adenovirus B	100	3,184.75	69,714.71
Human adenovirus C	171	573.87	10,160.48
Torque teno virus	135	484.19	1,935.97

## Figure Captions

**Fig. 1.** Number of detections by the Karius test of the different super groups of taxa, Apr 2018–Sept 2021, N=22,792: bacteria, 16,221; viruses, 4,737; fungi, 1,758; and parasites, 70. Percentages reflect proportion of total number of detections spanning 701 microbial taxa.

**Fig. 2.** Number of detected taxa counts per report for all positive reports, Apr 2018–Sept 2021. Percentages reflect the proportion of all positive reports (N=10,752).

**Fig. 3.** Frequency distribution of *Legionella*-like organisms detected, n=80 (<1% of all bacterial detections, N=16,203), Apr 2018–Sept 2021.

**Fig. 4.** Frequency distribution of *Nocardia* spp. detections, n=76 (<1% bacterial detections, N=16,203), Apr 2018–Sept 2021. \*Indicates species more frequently isolated from clinical specimens (66). †Indicates species-specific susceptibility patterns (51)

**Fig. 5.** Frequency distribution of *Mycobacterium* spp. detections, n=156 (1% of all bacterial detections, N=16,203), Apr 2018–Sept 2021. \*Indicates slowly growing mycobacteria of established clinical significance (67). †Indicates rapidly growing mycobacteria considered common human pathogens. ‡Indicates rapidly growing mycobacteria considered less common or rare human pathogens (68).

**Fig. 6.** Frequency distribution of zoonotic and vector borne bacteria detections, n=247 (2% of all bacterial detections, N=16,203), Apr 2018–Sept 2021. \*Indicates bacteria causing a nationally notifiable infectious disease (69).

**Fig. 7.** Frequency distribution of *Candida* spp. detections, n=648 (36% of all fungal detections, N=1,776), Apr 2018–Sept 2021.

**Fig. 8.** Frequency distribution of *Aspergillus* spp. detections, n=374 (21% of all fungal detections, n=1,776), Apr 2018–Sept 2021. \*Indicates most common pathogenic species.

**Fig 9.** Frequency distribution of detections in the order *Mucorales*, n=196 (11% of all fungal detections, N=1,776), Apr 2018–Sept 2021. \*Indicates taxa implicated in human mucormycosis (70).

**Fig 10.** Frequency distribution of detections of systemic dimorphic fungi, n=78 (4% of all fungal detections, N=1,776), Apr 2018–Sept 2021.

**Fig 11.** Frequency distribution of detections of dematiaceous fungi, n=33 (2% of all fungal detections, N=1,776), Apr 2018–Sept 2021.

**Fig 12.** Frequency distribution of detections of protozoan parasites, n=57 (89% of all eukaryotic parasite detections, N=64), Apr 2018–Sept 2021.

**Supplemental Table 1.** All 701 taxa detected in reports with number detected and median and interquartile range for quantification in molecules/ $\mu$ l (MPM) for each taxon, Apr 2018–Sept 2021. The top 50 detected are highlighted in **bold**.

Taxa name	Number detected	Median MPM	IQR
<i>Abiotrophia defectiva</i>	17	123.78	299.60
<i>Acanthamoeba</i>	1	12,186.93	0.00
<i>Acetobacter nitrogenifigens</i>	2	168.78	20.74
<i>Achromobacter insolitus</i>	1	37,178.62	0.00
<i>Achromobacter ruhlandii</i>	6	482.95	1,836.01
<i>Achromobacter xylosoxidans</i>	32	689.96	2,977.61
<i>Acidaminococcus intestini</i>	10	440.20	634.82
<i>Acidovorax citrulli</i>	2	53,316.31	37,869.12
<i>Acinetobacter baumannii</i>	27	289.72	809.16
<i>Acinetobacter bereziniae</i>	1	441.41	0.00
<b><i>Acinetobacter haemolyticus</i></b>	199	142.97	192.68
<i>Acinetobacter nosocomialis</i>	2	37.02	12.10
<i>Acinetobacter pittii</i>	10	419.25	1,648.00
<i>Acinetobacter radioresistens</i>	3	53.56	207.40
<i>Acinetobacter soli</i>	2	142.97	58.05
<i>Acinetobacter ursingii</i>	8	122.31	205.92
<i>Actinomyces europaeus</i>	1	54.51	0.00
<i>Actinomyces gerencseriae</i>	1	1,318.27	0.00

<i>Actinomyces graevenitzii</i>	39	145.47	205.79
<i>Actinomyces israelii</i>	10	89.85	180.58
<i>Actinomyces massiliensis</i>	1	82.41	0.00
<i>Actinomyces neuii</i>	4	2,279.05	25,827.25
<i>Actinomyces odontolyticus</i>	32	87.49	162.81
<i>Actinomyces oris</i>	25	134.56	124.41
<i>Actinomyces turicensis</i>	2	346.60	212.30
<i>Actinomyces viscosus</i>	45	87.93	98.10
<i>Adeno-associated dependoparvovirus A</i>	25	1,611.82	9,610.65
<i>Aerococcus christensenii</i>	2	466.47	402.10
<i>Aerococcus urinae</i>	2	3,266.81	2,733.34
<i>Aerococcus viridans</i>	2	61.26	36.48
<i>Aeromonas caviae</i>	13	69.51	84.93
<i>Aeromonas hydrophila</i>	1	197.69	0.00
<i>Aggregatibacter actinomycetemcomitans</i>	15	1,841.34	23,328.59
<i>Aggregatibacter aphrophilus</i>	29	1,041.16	18,934.90
<i>Aggregatibacter segnis</i>	24	664.17	1,392.99
<i>Agrobacterium tumefaciens</i>	7	123.86	41.69
<i>Alloscardovia omnicolens</i>	5	113.08	83.54
<i>Alphapapillomavirus 9</i>	4	14,786.35	29,889.21
<i>Alternaria alternata</i>	11	142.47	315.88
<i>Alternaria arborescens</i>	1	106.86	0.00
<i>Anaerobiospirillum succiniciproducens</i>	1	86.80	0.00

<i>Anaerococcus hydrogenalis</i>	2	763.57	645.00
<i>Anaerococcus lactolyticus</i>	2	495.87	213.92
<i>Anaerococcus prevotii</i>	2	72.70	27.37
<i>Anaerococcus tetradius</i>	3	2,981.82	1,234.60
<i>Anaeroglobus geminatus</i>	8	283.70	351.35
<i>Anaerostipes caccae</i>	5	963.17	458.19
<i>Anaplasma phagocytophilum</i>	6	27,154.21	120,865.63
<i>Anncaliia algerae</i>	1	117,297.14	0.00
<i>Arcanobacterium haemolyticum</i>	1	192.25	0.00
<i>Aspergillus calidoustus</i>	17	264.07	753.65
<i>Aspergillus chevalieri</i>	2	36.04	12.13
<i>Aspergillus flavus</i>	54	543.15	2,437.50
<b><i>Aspergillus fumigatus</i></b>	<b>186</b>	<b>300.10</b>	<b>723.60</b>
<i>Aspergillus glaucus</i>	3	64.01	25.74
<i>Aspergillus lentulus</i>	3	5,783.25	4,067.74
<i>Aspergillus luchuensis</i>	3	108.15	92,159.37
<i>Aspergillus niger</i>	23	150.50	403.84
<i>Aspergillus nomiae</i>	1	85.74	0.00
<i>Aspergillus nomius</i>	1	387.11	0.00
<i>Aspergillus novofumigatus</i>	1	214.80	0.00
<i>Aspergillus oryzae</i>	41	349.37	1,739.82
<i>Aspergillus pseudoterreus</i>	1	108.95	0.00
<i>Aspergillus ruber</i>	3	22.40	13.31

<i>Aspergillus sydowii</i>	3	80.90	16.85
<i>Aspergillus terreus</i>	12	399.25	1,965.25
<i>Aspergillus thermomutatus</i>	1	15.53	0.00
<i>Aspergillus tubingensis</i>	16	576.23	8,260.64
<i>Aspergillus udagawae</i>	3	48.37	103.09
<i>Atopobium parvulum</i>	18	122.20	203.85
<i>Atopobium rimae</i>	5	352.99	869.84
<i>Atopobium vaginae</i>	11	411.66	499.92
<i>Aureobasidium melanogenum</i>	1	13.31	0.00
<i>Aureobasidium pullulans</i>	3	336.28	947.39
<i>Aureobasidium subglaciale</i>	1	1,247.08	0.00
<i>Babesia microti</i>	1	162,139.56	0.00
<i>Bacillus cereus</i>	51	926.50	10,719.62
<i>Bacillus coagulans</i>	1	150.16	0.00
<i>Bacillus licheniformis</i>	1	73.56	0.00
<i>Bacillus megaterium</i>	1	144.20	0.00
<i>Bacillus subtilis</i>	1	75.10	0.00
<i>Bacillus thuringiensis</i>	11	358.99	3,434.89
<i>Bacteroides caccae</i>	52	98.68	308.62
<i>Bacteroides distasonis</i>	80	141.94	297.31
<i>Bacteroides eggerthii</i>	4	370.01	662.35
<i>Bacteroides faecis</i>	17	264.41	1,469.41
<i>Bacteroides forsythus</i>	2	50.32	0.95

<b><i>Bacteroides fragilis</i></b>	217	264.74	1,046.15
<i>Bacteroides merdae</i>	31	111.12	134.39
<b><i>Bacteroides ovatus</i></b>	133	141.43	476.14
<i>Bacteroides pyogenes</i>	2	132.40	13.83
<i>Bacteroides salyersiae</i>	2	4,234.08	2,497.91
<i>Bacteroides stercoris</i>	36	113.62	186.94
<b><i>Bacteroides thetaiotaomicron</i></b>	146	221.79	742.60
<i>Bacteroides uniformis</i>	90	182.90	380.86
<b><i>Bacteroides vulgatus</i></b>	392	153.01	413.32
<i>Balamuthia mandrillaris</i>	1	99.03	0.00
<i>Bartonella clarridgeiae</i>	3	759.52	2,412.20
<i>Bartonella henselae</i>	90	2,912.27	15,938.61
<i>Bartonella quintana</i>	5	36,551.67	40,236.66
<i>Bartonella vinsonii</i>	2	13,357.39	13,293.11
<i>Bergeyella zoohelcum</i>	1	113.67	0.00
<i>Bifidobacterium adolescentis</i>	1	54.54	0.00
<i>Bifidobacterium animalis</i>	4	155.74	138.28
<i>Bifidobacterium breve</i>	26	285.78	3,313.08
<i>Bifidobacterium dentium</i>	3	65.97	108.26
<i>Bifidobacterium longum</i>	39	196.50	457.04
<i>Bifidobacterium scardovii</i>	2	118.98	83.45
<i>Bipolaris papendorffii</i>	1	2,432.40	0.00
<b><i>BK polyomavirus</i></b>	354	472.38	2,677.18



<i>Blastomyces dermatitidis</i>	10	848.96	1,341.24
<i>Bordetella bronchiseptica</i>	2	4,526.17	4,177.42
<i>Bordetella hinzii</i>	1	128.84	0.00
<i>Bordetella pertussis</i>	2	92.47	43.01
<i>Bordetella trematum</i>	1	76.35	0.00
<i>Borrelia burgdorferi</i>	1	195.35	0.00
<i>Borrelia hermsii</i>	1	988.13	0.00
<i>Brachyspira pilosicoli</i>	1	92.04	0.00
<i>Brevibacterium casei</i>	10	131.21	284.45
<i>Brevundimonas diminuta</i>	3	132.30	392.15
<i>Brucella melitensis</i>	5	373.73	386.84
<i>Bulleidia extracta</i>	3	271.01	197.25
<i>Burkholderia ambifaria</i>	2	909.75	831.71
<i>Burkholderia anthina</i>	1	108.71	0.00
<i>Burkholderia cenocepacia</i>	4	233.10	667.72
<i>Burkholderia cepacia</i>	6	319.85	569.70
<i>Burkholderia cepacia complex</i>	46	105.98	270.69
<i>Burkholderia contaminans</i>	7	78.48	47.62
<i>Burkholderia gladioli</i>	5	136.42	160.50
<i>Burkholderia multivorans</i>	14	108.65	397.76
<i>Campylobacter coli</i>	1	550.26	0.00
<i>Campylobacter concisus</i>	27	203.89	336.72
<i>Campylobacter curvus</i>	4	159.86	213.02

<i>Campylobacter fetus</i>	3	398.01	1,838.80
<i>Campylobacter gracilis</i>	4	91.15	144.24
<i>Campylobacter jejuni</i>	6	230.28	219.37
<i>Campylobacter showae</i>	8	320.77	351.41
<i>Campylobacter upsaliensis</i>	2	69.79	19.83
<i>Campylobacter ureolyticus</i>	6	110.70	380.34
<b><i>Candida albicans</i></b>	260	624.63	2,074.97
<i>Candida carpophila</i>	5	15,987.23	22,145.87
<i>Candida dubliniensis</i>	38	1,130.01	2,173.12
<b><i>Candida glabrata</i></b>	113	611.85	1,449.20
<i>Candida kefyr</i>	4	195.64	1,330.87
<i>Candida krusei</i>	17	2,806.67	26,774.01
<i>Candida lusitanae</i>	5	840.07	645.34
<i>Candida orthopsilosis</i>	5	3,068.99	10,092.36
<i>Candida parapsilosis</i>	72	447.94	2,020.79
<b><i>Candida tropicalis</i></b>	103	784.49	3,997.85
<i>Candida utilis</i>	4	147.35	47.24
<i>Capnocytophaga canimorsus</i>	6	3,404.20	9,150.42
<i>Capnocytophaga gingivalis</i>	13	139.37	206.78
<i>Capnocytophaga granulosa</i>	1	304.45	0.00
<i>Capnocytophaga ochracea</i>	3	433.17	372.25
<i>Capnocytophaga sputigena</i>	15	95.80	296.68
<i>Cardiobacterium hominis</i>	26	8,419.91	23,662.49

<i>Cellulomonas flavigena</i>	4	87.77	83.74
<i>Chimpanzee alpha-1 herpesvirus</i>	3	6,380.71	15,691.54
<i>Chlamydia pneumoniae</i>	1	185.79	0.00
<i>Chlamydia trachomatis</i>	2	94.87	43.63
<i>Chlamydophila pneumoniae</i>	1	178.58	0.00
<i>Chromobacterium haemolyticum</i>	1	670.28	0.00
<i>Chryseobacterium indologenes</i>	2	846.11	538.86
<i>Citrobacter amalonaticus</i>	12	128.09	1,209.45
<i>Citrobacter braakii</i>	9	317.67	550.18
<i>Citrobacter freundii</i>	48	318.96	2,449.89
<i>Citrobacter koseri</i>	20	2,213.27	8,786.56
<i>Cladophialophora bantiana</i>	3	65.05	105.91
<i>Clavispora lusitaniae (Candida lusitaniae)</i>	4	2,031.99	6,036.17
<i>Clostridioides difficile (Clostridium difficile)</i>	10	418.00	1,377.85
<i>Clostridium baratii</i>	3	63.89	31.30
<i>Clostridium bifermentans</i>	1	12,394.39	0.00
<i>Clostridium butyricum</i>	14	359.16	1,482.07
<i>Clostridium cadaveris</i>	2	134,104.38	133,713.96
<i>Clostridium clostridioforme</i>	23	168.39	149.54
<i>Clostridium difficile</i>	11	359.74	839.88
<i>Clostridium hylemonae</i>	3	248.36	720.76
<i>Clostridium innocuum</i>	81	199.92	359.57
<i>Clostridium neonatale</i>	12	213.37	209.89

<i>Clostridium novyi</i>	1	2,231.87	0.00
<i>Clostridium paraputrificum</i>	8	113.22	379.46
<i>Clostridium perfringens</i>	25	145.68	3,153.06
<i>Clostridium sordellii</i>	2	399.72	333.56
<i>Clostridium ventriculi</i>	8	313.30	1,235.18
<i>Coccidioides immitis</i>	14	136.76	113.94
<i>Coccidioides posadasii</i>	4	179.60	828.91
<i>Comamonas kerstersii</i>	1	47.81	0.00
<i>Comamonas testosteroni</i>	1	3,272.81	0.00
<i>Conidiobolus incongruus</i>	1	48.23	0.00
<i>Corynebacterium accolens</i>	2	64.43	43.63
<i>Corynebacterium afermentans</i>	9	98.51	75.43
<i>Corynebacterium amycolatum</i>	27	496.48	809.76
<i>Corynebacterium aurimucosum</i>	13	81.42	136.10
<i>Corynebacterium diphtheriae</i>	3	4,891.94	3,193.06
<i>Corynebacterium freneyi</i>	1	47.98	0.00
<i>Corynebacterium jeikeium</i>	16	625.78	1,064.80
<i>Corynebacterium kroppenstedtii</i>	7	100.38	428.77
<i>Corynebacterium massiliense</i>	3	70.34	909.02
<i>Corynebacterium matruchotii</i>	6	127.24	247.41
<i>Corynebacterium minutissimum</i>	2	89.98	32.45
<i>Corynebacterium propinquum</i>	11	324.85	832.56
<i>Corynebacterium pseudodiphtheriticum</i>	2	12,671.39	12,436.87

<i>Corynebacterium riegelii</i>	1	423.76	0.00
<i>Corynebacterium striatum</i>	40	844.16	1,833.64
<i>Corynebacterium urealyticum</i>	2	382.25	270.50
<i>Corynebacterium ureicelerivorans</i>	1	358.20	0.00
<i>Corynebacterium xerosis</i>	1	36.10	0.00
<i>Coxiella burnetii</i>	10	1,059.25	6,607.37
<i>Cronobacter sakazakii</i> ( <i>Enterobacter sakazakii</i> )	3	238.87	9,741.76
<i>Cryptococcus gattii</i> VGIII ( <i>Cryptococcus bacillisporus</i> )	1	170.32	0.00
<i>Cryptococcus neoformans</i>	6	618.88	748.02
<i>Cryptosporidium hominis</i>	1	26.58	0.00
<i>Cryptosporidium parvum</i>	2	502.43	33.62
<i>Cunninghamella</i>	17	2,125.97	5,735.88
<i>Cupriavidus gilardii</i>	1	7,409.84	0.00
<i>Cupriavidus metallidurans</i>	4	118.73	133.91
<i>Curvularia lunata</i>	2	1,038.94	938.16
<i>Curvularia papendorfii</i> ( <i>Bipolaris papendorfii</i> )	1	364.16	0.00
<i>Cutibacterium granulorum</i> ( <i>Propionibacterium granulorum</i> )	1	430.63	0.00
<i>Cyberlindnera fabianii</i> ( <i>Hansenula fabianii</i> )	1	826.61	0.00
<i>Cyberlindnera jadinii</i> ( <i>Candida utilis</i> )	1	47.54	0.00
<i>Cyclospora cayetanensis</i>	1	34,376.00	0.00
<b><i>Cytomegalovirus (CMV)</i></b>	1275	633.93	3,889.67

<i>Delftia acidovorans</i>	3	145.56	656.29
<i>Dermacoccus nishinomiyaensis</i>	12	215.47	245.46
<i>Dialister microaerophilus</i>	1	3,320.59	0.00
<i>Dysgonomonas capnocytophagoides</i>	2	1,105.81	879.71
<i>Dysgonomonas mossii</i>	2	3,397.16	2,953.55
<i>Echinococcus multilocularis</i>	2	365.15	10.57
<i>Eggerthella lenta</i>	5	361.83	768.91
<i>Ehrlichia chaffeensis</i>	15	638,224.07	27,830,155.73
<i>Ehrlichia muris</i>	1	167,462.89	0.00
<i>Eikenella corrodens</i>	11	197.05	345.79
<i>Elizabethkingia anophelis</i>	3	1,740.10	1,595.66
<i>Encephalitozoon cuniculi</i>	1	138.90	0.00
<i>Encephalitozoon hellem</i>	1	738.90	0.00
<i>Entamoeba histolytica</i>	4	217.00	177.36
<i>Enterobacter aerogenes</i>	18	582.41	1,517.71
<b><i>Enterobacter cloacae complex</i></b>	343	821.34	6,742.30
<i>Enterobacter sakazakii</i>	1	69.47	0.00
<i>Clostridium clostridioforme</i>	26	228.09	873.58
<i>Enterococcus avium</i>	34	321.64	2,834.41
<i>Enterococcus casseliflavus</i>	12	80.85	717.36
<i>Enterococcus cecorum</i>	2	24.05	0.14
<i>Enterococcus durans</i>	11	1,163.27	5,902.22
<b><i>Enterococcus faecalis</i></b>	582	617.90	3,285.15

<b><i>Enterococcus faecium</i></b>	510	687.63	3,958.33
<i>Enterococcus gallinarum</i>	42	498.60	1,084.89
<i>Enterococcus gilvus</i>	1	14.74	0.00
<i>Enterococcus hirae</i>	1	2,013.10	0.00
<i>Enterococcus italicus</i>	1	22.57	0.00
<i>Enterococcus mundtii</i>	3	110.99	313.15
<i>Enterococcus raffinosus</i>	21	760.91	8,028.00
<i>Enterococcus saccharolyticus</i>	1	22.43	0.00
<i>Enterocytozoon bieneusi</i>	5	4,069.52	4,182.75
<b><i>Epstein-Barr virus (EBV)</i></b>	902	272.34	852.32
<i>Erwinia billingiae</i>	1	363.57	0.00
<i>Erysipelothrix rhusiopathiae</i>	2	112.31	46.47
<i>Escherichia albertii</i>	1	680.08	0.00
<b><i>Escherichia coli</i></b>	1088	684.92	3,623.17
<i>Eubacterium limosum</i>	3	161.41	3,525.21
<i>Eubacterium nodatum</i>	4	414.98	459.34
<i>Exophiala dermatitidis</i>	3	15,333.38	43,020.90
<i>Exophiala oligosperma</i>	1	120.68	0.00
<i>Exophiala sideris</i>	1	53.15	0.00
<i>Exophiala xenobiotica</i>	2	107.22	44.29
<i>Fenollaria massiliensis</i>	1	92.90	0.00
<i>Filifactor alocis</i>	11	180.11	503.01
<i>Filobasidium wieringae</i>	1	1,067.05	0.00

<i>Finegoldia magna</i>	10	66.60	154.12
<i>Fluoribacter bozemanæ (Legionella bozemanæ)</i>	5	696.51	172.05
<i>Francisella tularensis</i>	5	1,300.91	3,708.73
<i>Fusarium euwallaceae</i>	3	146.05	2,243.26
<i>Fusarium fujikuroi</i>	1	1,197.99	0.00
<i>Fusarium graminearum</i>	1	24.47	0.00
<i>Fusarium oxysporum</i>	3	424.38	612.34
<i>Fusarium proliferatum</i>	5	55.47	34.81
<i>Fusarium solani</i>	6	205.17	150.05
<i>Fusobacterium mortiferum</i>	7	462.67	2,476.66
<i>Fusobacterium necrophorum</i>	38	3,678.24	26,778.68
<b><i>Fusobacterium nucleatum</i></b>	299	460.25	1,922.08
<i>Fusobacterium periodonticum</i>	34	178.91	241.99
<i>Fusobacterium ulcerans</i>	5	55.62	49.69
<i>Fusobacterium varium</i>	2	49.18	23.25
<i>Gardnerella vaginalis</i>	34	138.12	203.18
<i>Gemella bergeri</i>	6	76,955.37	452,814.11
<i>Gemella haemolysans</i>	32	178.44	316.61
<i>Gemella morbillorum</i>	15	215.69	845.80
<i>Gemella sanguinis</i>	8	163.63	721.34
<i>Gleimia europaea (Actinomyces europaeus)</i>	2	103.94	33.67
<i>Gordonia aichiensis</i>	1	65.41	0.00
<i>Gordonia bronchialis</i>	6	219.80	71.67



<i>Gordonia terrae</i>	1	25.50	0.00
<i>Granulicatella adiacens</i>	34	273.92	1,115.83
<i>Granulicatella elegans</i>	4	169.28	252.13
<i>Graphilbum fragrans</i>	1	65.53	0.00
<i>Haemophilus haemolyticus</i>	23	205.44	720.41
<b><i>Haemophilus influenzae</i></b>	288	157.09	425.59
<i>Haemophilus parahaemolyticus</i>	9	184.28	338.82
<b><i>Haemophilus parainfluenzae</i></b>	178	284.92	1,121.19
<i>Haemophilus quentini</i>	11	125.14	219.98
<i>Haemophilus sputorum</i>	1	331.33	0.00
<i>Hafnia paralvei</i>	6	13,126.59	26,361.30
<i>Helicobacter bilis</i>	10	293.61	119.67
<i>Helicobacter cinaedi</i>	11	116.73	113.48
<i>Helicobacter fennelliae</i>	2	130.12	41.01
<i>Helicobacter magdeburgensis</i>	5	133.98	748.86
<b><i>Helicobacter pylori</i></b>	207	217.44	601.83
<b><i>Herpes simplex virus type 1 (HSV-1)</i></b>	479	754.78	3,208.06
<i>Herpes simplex virus type 2 (HSV-2)</i>	86	324.72	2,900.39
<i>Histoplasma capsulatum</i>	43	2,614.46	22,781.42
<i>Human adenovirus A</i>	30	3,030.46	31,375.54
<b><i>Human adenovirus B</i></b>	100	3,184.75	69,714.71
<b><i>Human adenovirus C</i></b>	171	573.87	10,160.48
<i>Human adenovirus D</i>	26	451.67	1,427.75

<i>Human adenovirus E</i>	1	107,282.84	0.00
<i>Human bocavirus</i>	29	1,220.78	5,360.88
<i>Human herpesvirus 6A</i>	54	182.72	697.25
<b><i>Human herpesvirus 6B</i></b>	468	518.74	3,268.72
<b><i>Human herpesvirus 7</i></b>	98	82.74	342.37
<i>Human papillomavirus 2</i>	2	47.34	3.09
<i>Human parvovirus</i>	5	239.40	2,068.01
<i>Human parvovirus B19</i>	11	8,084.47	15,721.03
<i>Human polyomavirus 6</i>	25	122.57	278.60
<i>Human polyomavirus 7</i>	8	269.11	681.14
<i>Janibacter indicus</i>	5	129.90	42.67
<i>JC polyomavirus</i>	52	224.82	417.80
<i>Kaposi sarcoma-associated herpesvirus</i>	42	593.21	4,796.06
<i>KI polyomavirus</i>	4	1,975.32	5,069.99
<i>Kingella denitrificans</i>	3	79.66	60.33
<i>Kingella kingae</i>	18	180.36	297.50
<i>Klebsiella aerogenes</i>	22	184.60	926.18
<i>Klebsiella aerogenes (Enterobacter aerogenes)</i>	45	3,056.44	6,026.75
<i>Klebsiella michiganensis</i>	53	1,210.50	10,222.36
<i>Klebsiella oxytoca</i>	31	542.85	2,449.33
<b><i>Klebsiella pneumoniae</i></b>	501	910.19	5,889.84
<i>Klebsiella quasipneumoniae</i>	32	431.21	12,757.58
<i>Klebsiella variicola</i>	56	655.76	4,440.31

<i>Kluyvera ascorbata</i>	2	258.18	136.69
<i>Kluyvera cryocrescens</i>	2	126.26	113.58
<i>Kluyveromyces marxianus (Candida kefyr)</i>	5	708.32	6,149.77
<i>Kocuria kristinae</i>	1	188.97	0.00
<i>Kocuria rhizophila</i>	9	114.18	742.54
<i>Kytococcus sedentarius</i>	15	131.57	375.38
<i>Lactobacillus acidophilus</i>	25	285.46	2,591.23
<i>Lactobacillus casei</i>	71	426.98	1,772.48
<i>Lactobacillus crispatus</i>	23	239.98	332.32
<b><i>Lactobacillus fermentum</i></b>	165	256.13	1,058.08
<i>Lactobacillus gasseri</i>	89	295.93	1,023.59
<i>Lactobacillus iners</i>	8	210.70	1,157.73
<i>Lactobacillus jensenii</i>	8	418.21	2,797.12
<i>Lactobacillus plantarum</i>	18	187.50	707.49
<b><i>Lactobacillus rhamnosus</i></b>	281	344.33	1,250.14
<i>Lactobacillus sakei</i>	2	97.72	76.11
<i>Lactobacillus ultunensis</i>	3	98.39	53.35
<i>Lactococcus garvieae</i>	1	52.98	0.00
<i>Lawsonella clevelandensis</i>	2	715.24	169.78
<i>Leclercia adecarboxylata</i>	2	80.78	37.28
<i>Legionella anisa</i>	3	2,719.09	2,035.94
<i>Legionella bozemaniae</i>	1	396,695.61	0.00
<i>Legionella bozemaniae</i>	3	391.47	418,155.06

<i>Legionella brunensis</i>	1	400.54	0.00
<i>Legionella cinclinatiensis</i>	1	76.45	0.00
<i>Legionella feeleeii</i>	6	1,093.57	7,557.04
<i>Legionella hackeliae</i>	1	270.00	0.00
<i>Legionella jordanis</i>	1	1,330.26	0.00
<i>Legionella longbeachae</i>	6	1,234.99	3,502.14
<i>Legionella maceachernii</i>	7	4,043.52	6,027.02
<i>Legionella micdadei</i>	3	14,462.63	12,364.41
<i>Legionella pneumophila</i>	33	3,071.64	70,034.47
<i>Legionella sainthelensi</i>	3	24,516.11	1,247,656.68
<i>Legionella tunisiensis</i>	1	76,444.86	0.00
<i>Leishmania panamensis</i>	1	3,351.42	0.00
<i>Lelliottia amnigena (Enterobacter amnigenus)</i>	1	34.22	0.00
<i>Leptospira borgpetersenii</i>	1	40.53	0.00
<i>Leptospira interrogans</i>	4	3,951.60	4,351.77
<i>Leptospira kirschneri</i>	6	837.62	244.70
<i>Leptospira noguchii</i>	1	382.24	0.00
<i>Leptospira santarosai</i>	2	331.11	47.28
<i>Leptotrichia buccalis</i>	1	578.89	0.00
<i>Leptotrichia goodfellowii</i>	2	598.58	464.03
<i>Leptotrichia shahii</i>	3	152.79	128.74
<i>Leptotrichia wadei</i>	9	681.54	664.48
<i>Leuconostoc citreum</i>	3	183.37	46.15

<i>Leuconostoc lactis</i>	10	429.96	1,566.93
<i>Leuconostoc mesenteroides</i>	5	65.09	97.47
<i>Lichtheimia corymbifera</i>	9	9,539.75	146,942.20
<i>Lichtheimia ramosa</i>	6	2,440.46	3,281.24
<i>Listeria monocytogenes</i>	3	299.93	51,690.46
<i>Lomentospora prolificans</i>	2	1,043.36	828.85
<i>Macrophomina phaseolina</i>	1	5,088.66	0.00
<i>Malassezia dermatis</i>	1	84.77	0.00
<i>Malassezia globosa</i>	19	109.37	131.24
<i>Malassezia obtusa</i>	1	294.10	0.00
<i>Malassezia slooffiae</i>	1	148.67	0.00
<i>Megasphaera micronuciformis</i>	18	300.41	825.26
<i>Merkel cell polyomavirus</i>	11	126.20	386.54
<i>Methanobrevibacter smithii</i>	6	1,386.70	7,847.25
<i>Meyerozyma carpophila (Candida carpophila)</i>	1	850.50	0.00
<i>Microbacterium maritypicum</i>	4	21,879.00	46,834.91
<i>Micrococcus luteus</i>	19	80.09	114.24
<i>Micrococcus lylae</i>	5	251.86	432.35
<i>Mogibacterium timidum</i>	3	2,569.39	1,946.72
<i>Molluscum contagiosum virus</i>	1	128.37	0.00
<i>Moraxella catarrhalis</i>	67	190.58	3,101.78
<i>Moraxella nonliquefaciens</i>	4	110.85	95.32
<i>Morganella morganii</i>	9	172.14	2,192.56

<i>Morococcus cerebrosus</i>	59	160.88	263.25
<i>Mucor circinelloides</i>	7	707.09	1,792.86
<i>Mucor indicus</i>	4	884.52	764.34
<i>Mucor velutinosus</i>	4	1,267.27	3,840.99
<i>Myceliophthora thermophila</i>	1	2,931.91	0.00
<i>Mycobacterium abscessus</i>	6	123.48	93.43
<i>Mycobacterium avium complex (MAC)</i>	43	1,009.09	6,486.08
<i>Mycobacterium brisbanense</i>	1	20.42	0.00
<i>Mycobacterium canariasense</i>	1	8,880.45	0.00
<i>Mycobacterium celatum</i>	1	135.09	0.00
<i>Mycobacterium chimaera</i>	18	1,311.56	4,304.26
<i>Mycobacterium fortuitum</i>	4	11,318.29	19,170.07
<i>Mycobacterium genavense</i>	1	2,789.10	0.00
<i>Mycobacterium haemophilum</i>	3	711.97	558.62
<i>Mycobacterium iranicum</i>	1	3,496.88	0.00
<i>Mycobacterium kansasii</i>	7	283.80	1,092.27
<i>Mycobacterium kyorinense</i>	1	193.95	0.00
<i>Mycobacterium mageritense</i>	3	77.31	13.50
<i>Mycobacterium mucogenicum</i>	2	2,373.76	2,352.27
<i>Mycobacterium neoaurum</i>	1	98.35	0.00
<i>Mycobacterium obuense</i>	1	28.27	0.00
<i>Mycobacterium szulgai</i>	1	613.94	0.00
<i>Mycobacterium tuberculosis complex</i>	31	529.86	1,839.79

<i>Mycobacterium xenopi</i>	1	145.68	0.00
<i>Mycobacteroides abscessus</i> ( <i>Mycobacterium abscessus</i> )	10	986.83	2,176.30
<i>Mycobacteroides chelonae</i> ( <i>Mycobacterium chelonae</i> )	3	99.55	11,021.03
<i>Mycolicibacterium brisbanense</i> ( <i>Mycobacterium brisbanense</i> )	1	31.90	0.00
<i>Mycolicibacterium chubuense</i> ( <i>Mycobacterium chubuense</i> )	1	60.58	0.00
<i>Mycolicibacterium elephantis</i> ( <i>Mycobacterium elephantis</i> )	1	124.16	0.00
<i>Mycolicibacterium flavescens</i> ( <i>Mycobacterium flavescens</i> )	1	111.66	0.00
<i>Mycolicibacterium fortuitum</i> ( <i>Mycobacterium fortuitum</i> )	1	6,851.84	0.00
<i>Mycolicibacterium goodii</i> ( <i>Mycobacterium goodii</i> )	1	54.03	0.00
<i>Mycolicibacterium holsaticum</i> ( <i>Mycobacterium holsaticum</i> )	1	108.30	0.00
<i>Mycolicibacterium mageritense</i> ( <i>Mycobacterium mageritense</i> )	3	46.13	132.81
<i>Mycolicibacterium mucogenicum</i> ( <i>Mycobacterium mucogenicum</i> )	4	138.57	58.87

<i>Mycolicibacterium obuense</i> ( <i>Mycobacterium obuense</i> )	1	174.52	0.00
<i>Mycolicibacterium phlei</i> ( <i>Mycobacterium phlei</i> )	1	100.16	0.00
<i>Mycoplasma fermentans</i>	1	46.76	0.00
<i>Mycoplasma genitalium</i>	1	72.01	0.00
<i>Mycoplasma hominis</i>	22	850.33	2,985.97
<i>Mycoplasma orale</i>	1	27,016.86	0.00
<i>Mycoplasma pneumoniae</i>	30	501.76	875.94
<i>Naegleria fowleri</i>	1	252,165.62	0.00
<i>Nectria haematococca</i>	8	214.71	264.23
<i>Neisseria bacilliformis</i>	6	84.41	125.81
<i>Neisseria cinerea</i>	19	189.75	436.40
<i>Neisseria elongata</i>	16	199.41	1,823.69
<i>Neisseria flavescens</i>	50	233.39	674.51
<i>Neisseria gonorrhoeae</i>	7	172.42	1,700.95
<i>Neisseria lactamica</i>	7	91.14	313.20
<i>Neisseria meningitidis</i>	4	742.84	923.05
<i>Neisseria mucosa</i>	65	263.79	747.92
<i>Neisseria polysaccharea</i>	1	2,405.17	0.00
<i>Neisseria sicca</i>	54	176.64	296.18
<i>Neisseria weaveri</i>	1	55.19	0.00
<i>Nocardia abscessus</i>	5	540.43	263.13
<i>Nocardia africana</i>	1	1,745.35	0.00



<i>Nocardia alba</i>	1	221.70	0.00
<i>Nocardia aobensis</i>	1	1,122.03	0.00
<i>Nocardia arthritidis</i>	1	316.63	0.00
<i>Nocardia asiatica</i>	2	634.77	331.76
<i>Nocardia beijingensis</i>	1	7,533.17	0.00
<i>Nocardia brasiliensis</i>	3	5,028.15	22,899.90
<i>Nocardia caishijiensis</i>	1	333.61	0.00
<i>Nocardia coubleae</i>	3	219.76	204.60
<i>Nocardia cyriacigeorgica</i>	19	2,114.43	5,435.89
<i>Nocardia elegans</i>	5	1,652.28	403.11
<i>Nocardia exalbida</i>	4	9,219.34	14,900.52
<i>Nocardia farcinica</i>	6	540.15	17,278.34
<i>Nocardia gamkensis</i>	4	8,265.16	15,257.72
<i>Nocardia ignorata</i>	2	223.45	40.99
<i>Nocardia kruczakiae</i>	1	3,074.36	0.00
<i>Nocardia niwae</i>	1	1,075.16	0.00
<i>Nocardia nova</i>	4	2,145.74	1,737.71
<i>Nocardia pseudobrasiliensis</i>	1	209.14	0.00
<i>Nocardia testacea</i>	3	6,458.07	3,689.88
<i>Nocardia thailandica</i>	2	160.57	9.99
<i>Nocardia transvalensis</i>	1	326.06	0.00
<i>Nocardia veterana</i>	3	248.21	1,373.42
<i>Nocardia violaceofusca</i>	1	1,513.97	0.00

<i>Ochrobactrum anthropi</i>	1	19.02	0.00
<i>Ochrobactrum intermedium</i>	6	67.40	44.55
<i>Odoribacter splanchnicus</i>	15	157.99	419.22
<i>Oligella urethralis</i>	1	95.29	0.00
<i>Olsenella uli</i>	5	304.72	222.00
<i>Ophiostoma piceae</i>	6	95.63	114.04
<i>Oribacterium sinus</i>	3	265.27	101.91
<i>Oscillibacter ruminantium</i>	1	2,177.92	0.00
<i>Pantoea agglomerans</i>	5	39.31	78.68
<i>Pantoea ananatis</i>	2	504.24	322.46
<i>Parabacteroides distasonis</i> ( <i>Bacteroides distasonis</i> )	79	269.11	630.70
<i>Parabacteroides goldsteinii</i>	11	111.63	126.15
<i>Parabacteroides johnsonii</i>	1	54.45	0.00
<i>Parabacteroides merdae</i> ( <i>Bacteroides merdae</i> )	23	267.04	826.60
<i>Paraburkholderia fungorum</i>	5	89.73	76.53
<i>Paracoccus sanguinis</i>	1	22.70	0.00
<i>Paracoccus yeei</i>	3	295.83	977.73
<i>Parvimonas micra</i>	38	265.51	1,536.56
<i>Pasteurella multocida</i>	9	261.01	4,081.62
<i>Pediococcus acidilactici</i>	8	484.76	1,576.94
<i>Pediococcus pentosaceus</i>	2	4,312.04	3,956.29
<i>Penicillium roqueforti</i>	4	131.69	88.00

<i>Peptoniphilus duerdenii</i>	1	193.15	0.00
<i>Peptoniphilus harei</i>	6	299.73	356.95
<i>Peptoniphilus lacrimalis</i>	3	3,704.81	1,953.46
<i>Peptoniphilus rhinitidis</i>	2	148.36	1.24
<i>Peptostreptococcus anaerobius</i>	8	743.25	997.75
<i>Peptostreptococcus stomatis</i>	10	310.75	1,377.27
<i>Pichia kudriavzevii (Candida krusei)</i>	11	284.86	604.41
<i>Plasmodium ovale</i>	1	8,863.02	0.00
<i>Pluralibacter gergoviae</i>	7	117.42	271.47
<b><i>Pneumocystis jirovecii</i></b>	258	2,452.78	18,084.89
<i>Porphyromonas asaccharolytica</i>	7	599.60	4,976.40
<i>Porphyromonas gingivalis</i>	27	527.97	2,360.78
<i>Prevotella bivia</i>	32	280.98	2,186.43
<i>Prevotella buccae</i>	12	202.19	235.67
<i>Prevotella buccalis</i>	2	432.39	338.45
<i>Prevotella corporis</i>	2	1,306.48	81.36
<i>Prevotella denticola</i>	49	321.99	646.21
<i>Prevotella disiens</i>	3	780.31	652.28
<i>Prevotella intermedia</i>	20	204.43	633.69
<i>Prevotella loescheii</i>	20	68.05	194.86
<b><i>Prevotella melaninogenica</i></b>	509	208.52	545.66
<i>Prevotella nigrescens</i>	26	124.86	309.78
<i>Prevotella oralis</i>	6	510.28	1,443.13

<b><i>Prevotella oris</i></b>	170	517.78	2,094.07
<i>Primate bocaparvovirus 1</i>	10	374.61	1,544.80
<i>Primate bocaparvovirus 2</i>	7	149.59	145.24
<i>Primate tetraparvovirus 1 (human PARV-4)</i>	1	264.41	0.00
<i>Propionibacterium acidifaciens</i>	7	81.74	112.48
<i>Propionibacterium granulosum</i>	4	77.79	49.63
<i>Propionibacterium namnetense</i>	8	236.38	505.49
<i>Propionibacterium propionicum</i>	5	39.72	35.85
<i>Proteus mirabilis</i>	50	366.80	1,256.61
<i>Providencia alcalifaciens</i>	2	41.88	12.50
<i>Providencia stuartii</i>	1	77.22	0.00
<b><i>Pseudomonas aeruginosa</i></b>	817	1,005.18	6,874.18
<i>Pseudomonas alcaligenes</i>	1	20,990.23	0.00
<i>Pseudomonas citronellolis</i>	9	89.74	52.47
<i>Pseudomonas fluorescens</i>	14	104.27	80.13
<i>Pseudomonas luteola</i>	5	34.43	28.69
<i>Pseudomonas mendocina</i>	17	65.14	56.50
<i>Pseudomonas mosselii</i>	3	257.67	312.30
<i>Pseudomonas oryzihabitans</i>	4	158.89	308.30
<i>Pseudomonas protegens</i>	5	98.79	116.08
<i>Pseudomonas pseudoalcaligenes</i>	50	85.61	106.20
<i>Pseudomonas putida</i>	8	105.42	160.56

<i>Pseudopropionibacterium propionicum</i> ( <i>Propionibacterium propionicum</i> )	5	114.00	151.83
<i>Pseudoramibacter alactolyticus</i>	1	72.02	0.00
<i>Psychrobacter cryohalolentis</i>	1	161.69	0.00
<i>Rahnella aquatilis</i>	6	84.27	129.68
<i>Raoultella ornithinolytica</i>	7	259.17	11,029.63
<i>Raoultella planticola</i>	1	29.14	0.00
<i>Rhizomucor miehei</i>	7	783.55	37,761.37
<i>Rhizomucor pusillus</i>	39	1,324.54	19,190.65
<i>Rhizopus delemar</i>	23	2,464.98	8,837.62
<i>Rhizopus microsporus</i>	33	1,205.05	5,120.17
<i>Rhizopus oryzae</i>	47	745.33	5,266.62
<i>Rhodococcus fascians</i>	1	43.24	0.00
<i>Rhodococcus hoagii</i> ( <i>Rhodococcus equi</i> )	1	98.24	0.00
<i>Rickettsia felis</i>	4	455.07	122,406.01
<i>Rickettsia rickettsii</i>	10	907.26	15,614.55
<i>Rickettsia typhi</i>	30	1,987.46	5,347.61
<i>Robinsoniella peoriensis</i>	3	4,572.89	5,006.42
<i>Roseomonas gilardii</i>	2	75.33	5.30
<i>Roseomonas mucosa</i>	3	95.21	418.92
<i>Rothia aeria</i>	9	454.35	441.59
<i>Rothia dentocariosa</i>	110	117.02	256.72
<i>Rothia mucilaginosa</i>	454	177.53	369.36

<i>Saccharomyces cerevisiae</i>	86	193.62	395.44
<i>Salmonella enterica</i>	24	265.52	1,156.82
<i>Scardovia wiggisiae</i>	2	87.25	7.15
<i>Scedosporium apiospermum</i>	8	190.34	146.48
<i>Scedosporium boydii</i>	5	106.65	424.87
<i>Scedosporium dehoogii</i>	1	381.08	0.00
<i>Schaalia meyeri</i> ( <i>Actinomyces meyeri</i> )	2	234.76	82.00
<i>Schaalia odontolytica</i> ( <i>Actinomyces odontolyticus</i> )	19	190.44	282.48
<i>Schistosoma mansoni</i>	1	277.44	0.00
<i>Serratia fonticola</i>	2	62,730.17	62,354.35
<i>Serratia liquefaciens</i>	3	9,877.18	1,221,938.81
<b><i>Serratia marcescens</i></b>	99	492.72	2,956.54
<i>Serratia rubidaea</i>	1	549.62	0.00
<i>Serratia ureilytica</i>	3	5,444.11	5,242.95
<i>Shigella dysenteriae</i>	1	173.68	0.00
<i>Shigella flexneri</i>	4	711.85	1,964.50
<i>Simian adenovirus 18</i>	1	36.28	0.00
<i>Slackia exigua</i>	4	598.89	72,838.71
<i>Sneathia amnii</i> ( <i>Leptotrichia amnionii</i> )	1	341.06	0.00
<i>Solobacterium moorei</i>	10	333.44	828.61
<i>Staphylococcus argenteus</i>	3	25,682.94	283,628.41
<i>Staphylococcus arlettae</i>	3	58.20	58.11

<b><i>Staphylococcus aureus</i></b>	561	838.21	5,665.43
<i>Staphylococcus auricularis</i>	1	86.31	0.00
<i>Staphylococcus capitis</i>	38	149.01	541.53
<i>Staphylococcus caprae</i>	6	236.48	130.57
<i>Staphylococcus cohnii</i>	11	76.82	130.69
<b><i>Staphylococcus epidermidis</i></b>	716	579.58	2,689.68
<b><i>Staphylococcus haemolyticus</i></b>	92	1,137.08	5,450.01
<i>Staphylococcus hominis</i>	54	141.13	154.11
<i>Staphylococcus lugdunensis</i>	10	254.58	283.24
<i>Staphylococcus pasteurii</i>	6	159.69	270.05
<i>Staphylococcus pettenkoferi</i>	6	122.64	126.34
<i>Staphylococcus pseudintermedius</i>	1	145.56	0.00
<i>Staphylococcus saprophyticus</i>	6	194.65	143.45
<i>Staphylococcus simulans</i>	2	154.46	55.44
<i>Staphylococcus succinus</i>	1	759.00	0.00
<i>Staphylococcus vitulinus</i>	1	615.92	0.00
<i>Staphylococcus warneri</i>	9	193.36	103.19
<i>Stenotrophomonas acidaminiphila</i>	2	40.38	4.36
<b><i>Stenotrophomonas maltophilia</i></b>	169	1,983.18	11,864.14
<i>Streptobacillus moniliformis</i>	6	202.09	238.18
<i>Streptococcus agalactiae</i>	71	1,683.20	8,449.36
<i>Streptococcus anginosus</i>	52	312.50	628.82
<i>Streptococcus canis</i>	2	465.07	256.92

<i>Streptococcus constellatus</i>	29	468.43	852.02
<i>Streptococcus cristatus</i>	3	444.40	211.52
<i>Streptococcus dentisani</i>	2	155.06	78.75
<i>Streptococcus dysgalactiae</i>	22	406.07	1,255.37
<i>Streptococcus equi</i>	2	6,266.23	5,506.19
<i>Streptococcus gallolyticus</i>	3	22,946.94	41,268.98
<i>Streptococcus gordonii</i>	20	180.63	491.75
<i>Streptococcus infantarius</i>	16	171.27	355.90
<i>Streptococcus infantis</i>	28	99.88	223.43
<b><i>Streptococcus intermedius</i></b>	100	354.95	1,048.47
<i>Streptococcus lutetiensis</i>	3	213.22	370.59
<i>Streptococcus macedonicus</i>	3	339.48	277.02
<i>Streptococcus massiliensis</i>	2	2,225.28	1,102.37
<b><i>Streptococcus mitis</i></b>	356	226.15	897.48
<i>Streptococcus mutans</i>	8	948.77	4,349.85
<b><i>Streptococcus oralis</i></b>	140	235.54	730.42
<i>Streptococcus oralis subsp. Dentisani</i> ( <i>Streptococcus dentisani</i> )	2	54,008.79	53,104.88
<i>Streptococcus oralis subsp. tigurinus</i> ( <i>Streptococcus tigurinus</i> )	14	141.23	673.16
<b><i>Streptococcus parasanguinis</i></b>	186	152.35	298.03
<i>Streptococcus pasteurianus</i>	9	2,240.75	2,414.70
<i>Streptococcus peroris</i>	20	106.46	245.34



<b><i>Streptococcus pneumoniae</i></b>	214	975.48	11,933.10
<i>Streptococcus pseudopneumoniae</i>	15	766.78	9,286.51
<b><i>Streptococcus pyogenes</i></b>	95	1,064.08	9,773.54
<b><i>Streptococcus salivarius</i></b>	104	253.73	799.10
<i>Streptococcus sanguinis</i>	27	269.26	1,348.95
<i>Streptococcus sobrinus</i>	3	96.96	173.72
<i>Streptococcus suis</i>	2	145.34	89.41
<b><i>Streptococcus thermophilus</i></b>	184	190.84	339.33
<i>Streptococcus tigurinus</i>	17	144.78	1,095.78
<i>Streptococcus vestibularis</i>	10	202.38	422.82
<i>Streptomyces cattleya</i>	16	114.74	55.64
<i>Strongyloides stercoralis</i>	4	1,512.96	9,478.02
<i>Sutterella wadsworthensis</i>	31	565.51	1,227.99
<i>Syncephalastrum monosporum</i>	2	568.75	6.29
<i>Tannerella forsythia</i>	5	473.15	207.68
<i>Tannerella forsythia (Bacteroides forsythus)</i>	6	174.58	2,910.62
<i>Tatlockia micdadei (Legionella micdadei)</i>	5	3,688.83	2,863.47
<i>Terrisporobacter othiniensis</i>	1	100.14	0.00
<i>Thermothelomyces thermophilus</i> <i>(Myceliophthora thermophila)</i>	1	7,097.68	0.00
<i>Thielavia terrestris</i>	1	4,992.52	0.00
Torque teno virus	135	484.19	1,935.97
Torque teno virus 1	7	236.02	200.42

Torque teno virus 10	19	427.60	963.21
Torque teno virus 12	9	289.68	1,425.06
Torque teno virus 15	48	354.03	808.26
Torque teno virus 16	69	314.22	883.45
Torque teno virus 19	8	150.95	221.08
Torque teno virus 27	5	580.18	395.77
Torque teno virus 28	13	501.20	1,455.28
Torque teno virus 3	6	1,069.93	1,952.05
Torque teno virus 6	25	235.89	1,976.02
Torque teno virus 7	4	313.65	39,910.86
Torque teno virus 8	3	141.72	75.53
<i>Toxoplasma gondii</i>	39	5,412.46	104,051.17
<i>Treponema pallidum</i>	9	8,026.35	18,627.59
<i>Trichoderma atroviride</i>	2	360.84	334.43
<i>Trichoderma gamsii</i>	1	20.36	0.00
<i>Trichoderma harzianum</i>	1	1,179.46	0.00
<i>Trichoderma longibrachiatum</i>	6	618.09	545.78
<i>Trichodysplasia spinulosa-associated polyomavirus</i>	34	321.17	2,290.78
<i>Trichomonas vaginalis</i>	5	676.48	10,184.71
<i>Trichosporon asahii</i>	14	488.22	1,544.34
<i>Trichosporon faecale</i>	1	38.11	0.00
<i>Tropheryma whipplei</i>	2	412.51	353.73

<i>Trypanosoma cruzi</i>	2	20,291.83	19,786.23
<i>Tsukamurella pulmonis</i>	1	34,399.13	0.00
<i>Ureaplasma parvum</i>	28	490.84	1,927.18
<i>Ureaplasma urealyticum</i>	14	256.95	6,202.13
Varicella-zoster virus (VZV)	48	1,856.17	7,412.46
<b><i>Veillonella dispar</i></b>	162	140.88	269.85
<b><i>Veillonella parvula</i></b>	256	202.30	476.57
<i>Verruconis gallopava (Ochroconis gallopava)</i>	1	228.74	0.00
<i>Vittaforma corneae</i>	1	147.95	0.00
<i>Walleimia mellicola</i>	2	79.97	13.00
<i>Weeksella virosa</i>	1	7,762.15	0.00
<i>Weissella confusa</i>	9	127.19	416.59
<i>Wickerhamomyces anomalus (Pichia anomala)</i>	2	1,656.22	12.29
<i>Winkia neuii (Actinomyces neuii)</i>	2	279.78	169.83
<i>WU Polyomavirus</i>	19	333.12	1,721.87

**Supplemental Table 2.** Reports with co-detections of *Legionella* spp., *Nocardia* spp., and *Mycobacterium* spp., April 2018–September 2021.

Sample number	Genus	Taxa name	MPM
1	<i>Legionella</i> spp.	<i>L. brunensis</i>	401
		<i>L. hackeliae</i>	270
		Epstein-Barr virus (EBV)	1,405
2	<i>Legionella</i> spp.	<i>L. feeleii</i>	78,508
		<i>L. tunisiensis</i>	76,445
		<i>Aspergillus fumigatus</i>	594
		<i>Encephalitozoon hellem</i>	739
3	<i>Nocardia</i> spp.	<i>N. alba</i>	222
		<i>N. caishijiensis</i>	334
		<i>N. coubleae</i>	495
		<i>N. ignorata</i>	182
		<i>N. thailandica</i>	171
		Human adenovirus D	747
		<i>Prevotella melaninogenica</i>	283
4	<i>Nocardia</i> spp.	<i>N. exalbida</i>	17,384
		<i>N. gamkensis</i>	22,906
5	<i>Nocardia</i> spp.	<i>N. exalbida</i>	2,153
		<i>N. gamkensis</i>	1,871
6	<i>Nocardia</i> spp.	<i>N. exalbida</i>	182
		<i>N. gamkensis</i>	242

		<i>BK polyomavirus</i>	81
		<i>Pseudomonas aeruginosa</i>	498
7	<b><i>Nocardia</i> spp.</b>	<b><i>N. elegans</i></b>	131
		<b><i>N. nova</i></b>	440
		<i>Actinomyces oris</i>	150
		<i>Bacteroides vulgatus</i>	215
		<i>Corynebacterium striatum</i>	1,590
		<i>Enterococcus faecalis</i>	296
		<i>Lactobacillus fermentum</i>	117
		<i>Lomentospora prolificans</i>	215
		<i>Prevotella buccae</i>	138
		<i>Prevotella oralis</i>	209
		<i>Rothia mucilaginosa</i>	874
		<i>Staphylococcus aureus</i>	364
		<i>Streptococcus salivarius</i>	1,032
		<i>Veillonella parvula</i>	122
8	<b><i>Nocardia</i> spp.</b>	<b><i>N. africana</i></b>	1,745
		<b><i>N. elegans</i></b>	6,314
		<b><i>N. nova</i></b>	3,945
		Cytomegalovirus (CMV)	12,597
9	<b><i>Nocardia</i> spp.</b>	<b><i>N. abscessus</i></b>	619
		<b><i>N. arthritidis</i></b>	317
		<b><i>N. asiatica</i></b>	303

10	<b><i>Nocardia</i> spp.</b>	<b><i>N. elegans</i></b>	1,556
		<b><i>N. nova</i></b>	2,720
11	<b><i>Nocardia</i> spp.</b>	<b><i>N. elegans</i></b>	1,652
		<b><i>N. nova</i></b>	1,572
12	<b><i>Nocardia</i> spp.</b>	<b><i>N. exalbida</i></b>	16,286
		<b><i>N. gamkensis</i></b>	14,660
		JC polyomavirus	337
13	<b><i>Nocardia</i> spp.</b>	<b><i>N. coubleae</i></b>	220
		<b><i>N. ignorata</i></b>	264
		<b><i>N. thailandica</i></b>	151
		Cytomegalovirus (CMV)	81
		Human adenovirus D	692
14	<b><i>Nocardia</i> spp.</b>	<b><i>N. aobensis</i></b>	1,122
		<b><i>N. kruzakiae</i></b>	3,074
		<b><i>N. violaceofusca</i></b>	1,514
		<i>Aspergillus fumigatus</i>	4,204
		BK polyomavirus	2,260
		Epstein-Barr virus (EBV)	49
		JC polyomavirus	61
15	<b><i>Mycobacterium</i> spp.</b>	<b><i>M. brisbanense</i></b>	20
		<b><i>M. mucogenicum</i></b>	21
		<b><i>M. obuense</i></b>	28
		<i>Stenotrophomonas acidaminiphila</i>	36

16	<b>Mycobacterium spp.</b>	<b><i>M. chubuense</i></b>	61	
		<b><i>M. elephantis</i></b>	124	
		<b><i>M. flavescens</i></b>	112	
		<b><i>M. goodii</i></b>	54	
		<b><i>M. holsaticum</i></b>	108	
		<b><i>M. phlei</i></b>	100	
			<i>Neisseria meningitidis</i>	62
17	<b>Mycobacterium spp.</b>	<b><i>M. avium complex (MAC)</i></b>	441	
		<b><i>M. celatum</i></b>	135	
		<b><i>M. kyorinense</i></b>	194	
			Epstein-Barr virus (EBV)	155
			<i>Prevotella melaninogenica</i>	398
			<i>Rothia mucilaginosa</i>	913
			<i>Veillonella dispar</i>	236
		<i>Veillonella parvula</i>	122	
18	<b>Mycobacterium spp.</b>	<b><i>M. avium complex (MAC)</i></b>	8,039	
		<b><i>M. chimaera</i></b>	2,410	
19	<b>Mycobacterium spp.</b>	<b><i>M. avium complex (MAC)</i></b>	104	
		<b><i>M. chimaera</i></b>	104	
20	<b>Mycobacterium spp.</b>	<b><i>M. complex (MAC)</i></b>	36,867	
		<b><i>M. chimaera</i></b>	36,862	

Fig. 1. Number of detections by the Karius test of the different super groups of taxa, Apr 2018–Sept 2021, N=22,792: bacteria, 16,221; viruses, 4,737; fungi, 1,758; parasites, 70. Percentages reflect proportion of total number of detections.






Fig. 2. Number of detected taxa counts per report for all positive reports, Apr 2018–Sept 2021. Percentages reflect the proportion of all positive reports (N=10,752).




Fig. 3. Frequency distribution of different *Legionella*-like organisms detected, n=80 (< 1% of all bacterial detections, N=16,203). \*Indicates species not previously detected in humans.




Fig. 4. Frequency distribution of *Nocardia* spp. detections, n=76 (< 1% bacterial detections, N=16,203). \*Indicates species more frequently isolated from clinical specimens (69). †Indicates species-specific susceptibility patterns (54).




Fig. 5. Frequency distribution of *Mycobacterium* spp. detections, n=156 (1% of all bacterial detections, N=16,203). \*Indicates slowly growing mycobacteria of established clinical significance (70). †Indicates rapidly growing mycobacteria considered common human pathogens. ‡Indicates rapidly growing mycobacteria considered less common or rare human pathogens (71).




Fig. 6. Frequency distribution of zoonotic and vector borne bacteria detections, n=247 (2% of all bacterial detections, N=16,203). \*Indicates bacteria causing a nationally notifiable infectious disease (72).




Fig. 7. Frequency distribution of *Candida* spp. detections, n=648 (36% of all fungal detections, N=1,776).




Fig. 8. Frequency distribution of *Aspergillus* spp. detections, n=374 (21% of all fungal detections, N=1,776). \*Indicates most common pathogenic species.




Fig 9. Frequency distribution of detections in the order Mucorales, n=196 (11% of all fungal detections, N=1,776). \*Indicates taxa implicated in human mucormycosis (73).






Fig 10. Frequency distribution of detections of systemic dimorphic fungi, n=78 (4% of all fungal detections, N=1,776).




Fig 11. Frequency distribution of detections of dematiaceous fungi, n=33 (2% of all fungal detections, N=1,776).




Fig 12. Frequency distribution of detections of protozoan parasites, n=57 (89% of all eukaryotic parasite detections, N=64).

